Dolat Preferred

DOLAT CAPITAL
India Research
Sector
Key issues pending /

likely to come up
Likely timeline
Qualitative Impact /
Oil & Gas
Gas price hike
End of Q2FY15
Significant, as it impacts ONGC and RIL

the most and the sentiment on sector /
economy
Vodafone
Retrospective
None
If Vodafone is made to finally pay up, it

will adversely affect the sentiments.
GST
States share for higher

compensation
Ongoing
Significant progress made by offering

higher compensation to states showing
the intent of the Finance Ministry to go all
out for GST. Implementation timeline of
Q1FY16 looks challenging, hence placing
our bets on H2FY16. Benefit for the
organised sectors, and the structural
trajectory of the tax / GDP
Fuel Subsidies
LPG, Kerosene
Diesel post
None
LPG subsidies being brought down on

similar lines as diesel by monthly hikes
could be a positive. Diesel subsidies will
be eliminated by Q3FY15 at the current
equation. However we keep our fingers
crossed on if will the oil companies will go
further if the need arises.
Near term valuations in fair range, FY16 earnings of high teens critical
to sustain
We see the current valuations of high teens on FY15 earnings as fair range.
We see these sustaining in the range at least till mid Q3FY15 by which
better visibility on FY16 earning trajectory shall emerge. If it does improve,
from our base case of mid teens earnings growth, we expect the valuations
to sustain. Further gains in these shall be driven by the quality of balance
sheet restructuring that the corporate go through.
Our interaction corroborate our base case assumption that the good part
of FY15 shall go into that exercise and earnings trajectory will be on the
upside FY16 onwards. This also coincides with the tailwinds on rate cycle
softening Q4FY15 onwards, and subsidies overhang on the fiscal wearing
off after five years. Though not in the consensus as of now, we believe
high teens sort of earnings for FY16 could be fair probability event. In
particular, the cyclicals and energy shall be decisive to high teens earnings
growth visibility. Our current estimates build in mid teens earnings visibility
for FY16.
While the interest in India remains high for FIIs and we continue to build in
consistent in flows for the secondary markets. However, our near term
concerns centre around the supply of fresh equity offering likely to hit the
market in between now and December. This could lead to consolidation
phase like the one we saw post election results to now.
Amit Khurana - Head of Research

Tel : +9122 4096 9745
E-mail: [email protected]
India Research
DOLAT CAPITAL
Keep conviction alive! But pay right price critical to portfolio construction
Whats In and Whats Out on Preferred Buy List*
In Preferred Buy
Why?
Axis Bank
As the investment cycle and money flow within the economy improves,
the bank can see a reasonable amount of deflation in its stressed assets
pool.
Biocon
Recent correction provides attractive opportunity to enter the stock with

strong biz model.
Crompton Greaves
Expect recovery in earnings from H2FY15 onwards led by improved

performance in the international subsidiaries. Domestic business
to be beneficiary of expected recovery in capex cycle.
KPIT Tech
We believe the weak Q1 has set the floor on margins and stock
performance. We are in sync with the management view that the weak
result was a function of poor execution rather than any challenges on the
business momentum.
Larsen & Toubro
Proxy play on recovery in infrastructure spend in India. Recent correction

provides attractive opportunity to enter the stock.
PTC India Financial (PFS)
All set to leverage upon the growth opportunities in the renewable energy
segment, especially solar power. Current CRAR of 26% sufficient to fuel 2
years of high growth.
Out of Preferred Buy
Why?
Asian Paints
There has been a recent run-up in the stock price and Valuations remain
high
Engineers India
With two large potential orders out of the way, near term earnings
visibility has deteriorated.
IPCA Labs
We believe the inspection observation (Form 483) will be an overhang

on the stock price in the near term given the uncertainty regarding the
timelines for resolution
Karur Vysya Bank
An improvement in overall asset quality is likely to be back-ended in

FY15. Current valuations do not provide a favourable risk reward
trade-off
Maruti Suzuki
The company is the only pure PV play in the listed space, however the
sharp run up in the last couple of months makes valuation look
expensive
State Bank of India
Stress levels still elevated, rich valuations do not offer large upsides.
Suprajit Engineering
Fundamentals stand intact, however valuations look expensive at

current levels
Voltas
Potential upside remains capped post the recent run-up. Delayed

execution could be a potential threat to the companys targeted
margins.
* With reference to our note dated 9th June 2014

Tel : +9122 4096 9745
India Research
DOLAT CAPITAL
Nifty EPS & P/E Estimates
E: Bloomberg Estimates,
Source: Bloomberg
Source: Bloomberg

Tel : +9122 4096 9745
India Research
DOLAT CAPITAL
Source: Bloomberg

Tel : +9122 4096 9745
DOLAT CAPITAL
India Research
Earnings Growth Aggregates
Growth(% Ex Banking)
FY15E
FY16E
Sales
EBITDA
EBITDA Margin(%)
PAT
11.8
11.6
18.8
12.0
14.1
17.8
18.8
18.0
Growth (% Banking)
FY15E
FY16E
17.3
20.4
16.8
19.5
21.9
28.7
NII
Operating Income
PAT
Revision in Estimates
FY15E
FY16E
1.5
1.3
1.9
2.5
1.0
2.2
Revision in Estimates
FY15E
FY16E
(1.5)
(1.3)
(1.6)
(1.3)
(2.4)
(1.7)
Earnings Growth Aggregates - Unbundled

Agro-Chemical
Particulars
FY15E
Growth(%)
FY16E
Sales
EBITDA
EBITDA Margin
PAT
18
26
17.4
23
20
23
17.8
25
Capital Goods
Particulars
FY15E
Growth(%)
FY16E
Sales
EBITDA
EBITDA Margin
6
(5)
10.3
14
25
11.3
(6)
29
PAT
Energy
Particulars
Sales
EBITDA
EBITDA Margin
PAT
Pharmaceuticals
Particulars
Sales
EBITDA
EBITDA Margin
PAT

Tel : +9122 4096 9745
Growth(%)
FY15E
FY16E
3
11
8.8
4
6
10
9.1
17
Growth(%)
FY15E
FY16E
19
16
27.4
10
16
18
28.0
18
Auto and Ancillary

Particulars
Sales
EBITDA
EBITDA Margin
PAT
Cement
Particulars
Sales
EBITDA
EBITDA Margin
PAT
Consumer
Particulars
Sales
EBITDA
EBITDA Margin
PAT
IT Services
Particulars
Sales
EBITDA
EBITDA Margin
PAT
FY15E
Growth(%)
FY16E
12
11
14.9
16
13
16
15.2
18
FY15E
Growth(%)
FY16E
13
25
18.2
17
33
20.7
25
32
Growth(%)
FY15E
FY16E
15
18
22.2
18
16
18
23.5
19
Growth(%)
FY15E
FY16E
13
12
24.3
12
14
15
24.6
14
10
DOLAT CAPITAL
India Research
Revisions to Earnings
Company
Larsen & Toubro
OFSS
Rallis
Titan Ind
Cummins
ITC
Crompton Greaves
Voltas
TCS
Net Sales (%)

18.9
9.1
5.9
2.7
2.6
2.5
2.4
2.1
1.6
Karur Vysya Bank
1.5
Company
Net Sales (%)
Thermax
Eclerx
Ipca Labs
ICICI Bank
Engineers India
PI Industries
NIIT Tech
HDFC Bank
KPIT Cummins
Page Ind

Tel : +9122 4096 9745
-8.5
-7.6
-7.2
-6.8
-6.2
-5.6
-3.1
-3.0
-3.0
-3.0
FY15E (Top Ten Upgrades)

Company
EBITDA (%)
Whirpool
23.6
Voltas
21.4
OFSS
12.7
Cadila Healthcare
10.3
Lupin
8.3
Titan Ind
7.2
HUL
4.4
Rallis
4.3
Tata Motors
4.2
Company
Triveni Turbine
Whirpool
Voltas
Cadila Healthcare
JK Lakshmi Cement
Lupin
OFSS
Titan Ind
TCS
ING Vysya Bank
Tata Motors
3.4
FY15E (Top Ten Downgrades)

Company
EBITDA (%)
Company
Engineers India
Thermax
Eclerx
Ipca Labs
KPIT Cummins
NIIT Tech
Tech mahindra
ICICI Bank
Persistent
Mphasis
Thermax
Engineers India
Eclerx
Ipca Labs
Union Bank
NIIT Tech
Larsen & Toubro
ICICI Bank
Persistent
KPIT Cummins
-26.2
-14.6
-11.3
-11.2
-11.1
-10.2
-6.9
-6.8
-5.7
-5.2
PAT (%)
43.5
26.0
20.8
9.3
7.2
6.7
5.2
4.1
3.8
3.3
PAT (%)
-21.9
-16.1
-13.3
-12.9
-10.4
-9.9
-8.2
-8.1
-7.5
-5.9
11

Tel : +9122 4096 9745
*From our last note dated June 9, 2014, Price as of August 22, 2014
Our Preferred Picks* v/s Benchmark Indices (QTD)
India Research
DOLAT CAPITAL
12
DOLAT CAPITAL
India Research
Sector Stance
Sector
Stance
Key Arguments
Automobile
Neutral
Domestic demand expected to pickup in H2FY15,

however factored in the valuations.
Capital Goods
Positive
Expect recovery in orderbook from H2FY15.
Cement
Positive
Demand recovery post H2FY15 onwards.
Consumer
Neutral
Raising weightage on discretionary and organised

plays.
Energy
Neutral
Prefer stock specific approach.
Financials
Positive
Private banks are likely to outperform in the medium

term before the asset quality cycle leads to another
round of re-rating in PSBs.
IT Services
Neutral
Cutting back on IT as INR remains elevated, and

allocations move towards cyclicals.
Pharma
Positive
Still retain our weightage on sustenance of earnings

trajectory.

Tel : +9122 4096 9745
13
DOLAT CAPITAL
DOLAT PREFERRED BUY PICKS
India Research
Sector
Top Picks
Large Cap
Automobile
Bajaj Auto
Capital Goods Crompton Greaves
P/E
ROE(%)
EV/EBIDTA (x)
Mcap/Sales (x)
FY14 FY15E FY16E
FY14 FY15E FY16E
FY14 FY15E FY16E
19.1
17.5
14.9
38.6 35.2
34.1
15.6 13.8
11.2
3.2
2.9
2.5
51.8
27.0
16.2
18.1
21.0 15.1
10.9
1.0
0.9
0.8
6.8
12.3
FY14 FY15E FY16E
L&T
31.3
30.7
22.0
12.8
11.9
15.2
20.1 21.1
17.5
1.7
1.5
1.2
Cement
Ultratech Cement
30.3
24.1
16.1
12.8 14.3
15.8
16.2 12.8
10.3
0.4
0.3
0.3
Consumer
Pharma
Pidilite Ind.
Divis Lab
Lupin
42.8
26.7
30.5
34.4
22.5
24.9
27.7
18.9
20.6
24.3 25.1
28.0 27.4
30.9 29.1
25.7
27.0
27.4
27.0 23.0
19.6 16.3
17.8 13.8
19.0
13.6
11.1
4.4
7.9
4.8
3.8
6.6
4.0
3.2
5.5
3.4
Sector
Top Picks
Mid/Small Cap
P/E
ROE(%)
EV/EBIDTA (x)
FY14 FY15E FY16E
FY14 FY15E FY16E
31.8
25.9
20.2
30.7 29.1
28.8
20.9 16.0
Agrochem
PI Industries
Automobile
Balkrishna Ind
14.3
13.0
10.3
29.3 24.9
24.6
10.5
Cement
Consumer
JK Lakshmi Cement
Relaxo Footwares
Whirlpool India
32.2
36.4
45.5
25.9
27.6
27.1
16.8
20.8
20.1
9.0 10.5
24.0 24.0
16.6 21.8
14.5
25.0
22.8
IT
KPIT Technologies
11.2
9.6
8.7
21.4 20.5
18.9
Mphasis
12.7
12.1
9.5
14.5 14.6
17.3
Midcap
Pharma
Astral Poly
Biocon
59.9
22.9
38.1
20.2
27.8
15.9
27.9 32.7
14.5 14.7
32.9
16.8
Sector
Top Picks
Large Cap
Mcap/Sales (x)
FY14 FY15E FY16E
P/E
13.5
7.1
13.2
7.8
Banks
Axis Bank
Bank of Baroda
ICICI Bank
Punjab Nat. Bank
15.2
8.6
14.4
10.7
Sector
Mid/Small Cap
Top Picks
P/E
FY14 FY15E FY16E
Banks/ NBFC
City Union Bank

PTC Financial
Yes Bank
12.2
8.9
13.0
11.6
6.2
11.8
12.3
3.8
3.1
2.6
9.1
7.2
2.0
1.7
1.4
15.9 12.4
17.4 14.1
25.3 15.8
8.2
11.3
11.8
1.7
1.9
2.0
1.4
1.6
1.7
1.1
1.3
1.4
5.5
1.0
0.9
0.8
7.3
6.6
7.3
7.1
5.6
1.5
1.5
1.3
27.1 19.9
15.1 12.9
14.9
9.7
4.3
3.6
3.3
3.1
2.6
2.4
P/ABV (x)
FY14 FY15E FY16E

11.0
5.7
11.0
5.8
9.2
4.6
9.4
ROE(%)
FY14 FY15E FY16E

2.5
1.4
2.4
1.5
2.2
1.2
2.2
1.3
1.9
1.1
1.9
1.1
P/ABV (x)
FY14 FY15E FY16E
2.3
1.4
3.0
1.9
1.2
2.1
FY14 FY15E FY16E
1.6
1.1
1.7
ROA (x)
FY14 FY15E FY16E

17.4
13.8
17.0
10.2
17.1
15.0
16.4
12.6
18.2
16.3
17.5
15.2
ROE(%)
FY14 FY15E FY16E
18.3 16.9
16.1 20.6
25.0 21.7
17.3
23.1
20.0
FY14 FY15E FY16E

1.7
0.8
1.7
0.7
1.7
0.8
1.7
0.8
1.8
0.8
1.8
0.9
ROA (x)
FY14 FY15E FY16E
1.4
5.0
1.6
1.5
4.2
1.7
1.6
3.3
1.8
* Gulf Oil detailed estimates not available

Prices as of August 22, 2014

Tel : +9122 4096 9745
14
DOLAT CAPITAL
KEY FILTERS PREFERRED BUY
India Research
Companies
CAGR Sales
CAGR PAT
OCF >
FCF
ROE >
D/E <
FY14-16E
FY14-16E
Capex
Positive
20%
0.4
Astral Poly
29%
47%
Bajaj Auto
13%
14%
Balkrishna Ind.
18%
18%
Biocon
24%
21%
Crompton Greaves
11%
79%
Divis Lab
20%
19%
Gulf Oil Corp*
9%
12%
JK Lakshmi Cement
25%
38%
KPIT Tech
12%
14%
Larsen & Toubro
16%
19%
Lupin
19%
22%
Mphasis
7%
16%
PI Industries
21%
26%
Pidilite Industries
18%
24%
Relaxo Footwear
21%
33%
Ultratech Cement
16%
24%
Whirlpool India
18%
51%
CAGR NII
CAGR PAT
ROE >
ROA >
P/ABV
NNPA<
FY14-16E
FY14-16E
17%
1%
< 1.2
1%
AXIS
17%
18%
BOB
22%
23%
CUB
18%
20%
ICICI Bank
15%
14%
PNB
14%
36%
PFS
74%
40%
Yes Bank
23%
26%
Companies
* Gulf Oil detial estimates note available

Tel : +9122 4096 9745
15

Tel : +9122 4096 9745
150
440
823
474
1556
1251
28
92
46
95
207
560
402
920
78
1,538
984
43
584
949
387
47
1,779
348
24
242
386
400
441
202
24
58
Axis Bank
Bank of Baroda
City Union Bank
ICICI Bank
Punjab National Bank
PTC Financial
Yes Bank
305
2,651
36
723
CMP
`)
(`
202
1,541
Mcap
(`
` bn)
523
455
1,070
85
1,730
1,150
54
673
TP
`)
(`
537
1648
1455
888
190
585
417
450
483
309
2,851
240
1694
2,263 2419.8
723 775.56
439
CMP Target
`)
`)
(`
(`
130
1,428
653
70
60
Mcap
` bn)
(`
Financials
Agrochemical
PI Industries
Auto
Bajaj Auto
Balkrishna Ind
Capital Goods
Cropmton Greaves
L&T
Cement
JK Lakshmi Cement
Ultratech Cement
Consumer
Pidilite Ind.
Relaxo Footwear
Whirlpool India
IT Services
KPIT Technologies
Mphasis
Midcap
Astral Poly Technik
Pharmaceuticals
Biocon
Divis Lab
Lupin
Companies
DOLAT PREFERRED PICKS
13
16
8
13
17
26
15
Upside
(%)
13
6
16
27
33
8
13
10
1
8
19
10
7
7
19
Upside
(%)
119,516
119,653
7,594
164,756
161,460
2,117
27,163
FY14
28,773
25,321
112,865
10,732
26,940
25,939
42,832
12,120
28,331
20,566
200,779
134,806
851,284
201,583
35,767
15,869
2,890
259,449 41,552
49,728 8,938
23,404
45,249
10,389
3,728
54,086
12,503
4,716
` mn)
EBIDTA (`
FY14
FY15E
FY16
17,961
33,652
70,792
59,250
17,652
39,508
138,279
144,667
8,676
182,723
178,476
3,779
33,725
`)
NII (`
FY15E
164,765
177,301
10,581
219,215
211,299
6,376
41,080
FY16E
33,525
43,441
30,360
36,542
135,925 158,944
13,964
29,650
62,087
50,344
14,664
33,173
25,210
31,925
233,190 271,412
8,063
12,205
38,059
2,053
4,062
9,548
8,053
1,798
3,288
4,130
46,291
10,643
14,726
46,094
2,658
4,889
12,161
9,689
2,203
4,179
6,065
58,177
114,561
92,910
5,810
165,947
113,847
3,162
26,880
128,771
112,216
6,470
180,594
124,026
5,160
34,501
153,280
136,262
8,150
213,551
146,988
7,015
42,635
`)
Operating Income(`
FY14
FY15E
FY16E
6,871
10,145
30,028
1,557
3,669
3,893
6,770
1,465
2,100
3,020
36,160
149,618
166,404
6,820
9,833
13,814
973,733 1,151,687 107,543 105,129 134,916
223,967
41,336
19,094
` mn)
Net Sales (`
FY14
FY15E
FY16E
13.8
17.0
21.8
5,966
10,938
27,140
1,664
3,211
9,757
7,103
1,155
2,788
213
32,888
7,830
64,970
12.5
70.1
23.5
69.0
50.3
21.6
15.6
36.5
11.2
14.5
16.3
29.8
82.4
60.6
29.6
17.3
46.4
13.9
19.2
22.0
11.8 18.1
94.9 119.9
7.5
50.2
`)
ABVPS(`)
FY14 FY15E FY16E
20.7
58.3
41.0
13.7
13.4
14.4
9.0
11.0
9.7
9.5
75.6
3.9
49.3
43,763 117.9 128.6 151.2

6,815 50.5 55.7 70.5
2,966
` mn)
PAT (`
FY15E
FY16E
4,697
9,164
22,515
1,215
2,885
7,660
5,731
872
2,064
1,385
26,018
4,691
46,547
37,216
5,389
2,312
FY16E
`)
EPS (`
FY14 FY15E FY16E
62,177 70,213 85,853 26.5 29.9 36.5

45,411 55,732 69,252 106.4 129.4 160.8
3,471
3,981
5,012
6.4
6.8
8.5
98,106 106,652 127,996 84.9 92.3 110.8
33,426 45,913 61,784 92.3 126.8 170.6
2,077
3,012
4,002
3.7
5.4
7.1
16,178 20,473 25,670 44.9 49.4 61.9
FY14
4,138
7,733
18,363
772
2,489
3,027
4,619
656
1,229
1,115
21,445
2,443
45,680
33,803
4,884
1,881
` mn)
PAT (`
FY14E
FY15E
India Research
DOLAT CAPITAL
16
Agrochemical
India Research
DOLAT CAPITAL
PI Industries (CMP: ` 439, TP: ` 523, Mcap: ` 60bn)
PI continues to build upon its strengths in the domestic agri

and custom synthesis, and delivering earnings to sustain high
teens valuations. We expect growth trajectory to go up
another notch as Jambusar Phase 2 and 3 start in FY16.
Key Assumption
Medium term visibility remains strong at the CSM business

with order book at USD 395 mn. Domestic business growth
also showing up potential for sustained growth with pipeline
of new products next few quarters two new launches for
FY15 confirmed.
Domestic Agri
Particulars
FY14 FY15E FY16E
Custom Synthesis
55
22
25
19
18
20
EBIDTA Margin
19
20
21
PAT Margin (%)
12
12
13
Export Growth (%)

Inputs Growth (%)
We believe given the base that PI has created couple of years, it is now in a position to self
sustain medium term growth of 20% and above, without having to dilute on its margins. The
strong return ratios and cash flow generation are other arguments for us keep the stock in our
preferred picks universe.
Key risk to our estimates could emanate from rupee volatility. Also, the visibility on CSM business
needs to sustain though we are not looking to decipher it on a sequential basis.
PI remains our preferred pick in the agri space with strong visibility and scalability to drive earnings
next couple of years. We expect consolidated revenue to grow by 21% CAGR during FY14-16E
on the back of higher contribution from the CSM business (From 52% in FY13 to 61% in FY16).
We expect PAT to grow by 26% CAGR during FY14-FY16E, and cash flow generation to
accelerate FY16 onwards. The stock is currently trading at 25.9x and 20.2x FY15 and FY16 EPS
respectively. We recommend Accumulate with a target price of ` 523. (24x FY16 EPS)
Head of25,
Research:
August
2014 Amit Khurana
Tel : +9122 4096 9745
Associate: Afshan Sayyad

Tel : +9122 4096 9726
17
DOLAT CAPITAL
Agrochemical - Annual Estimates
India Research
Companies
FY14
PI Industries
Rallis
Companies
15,869
17,466
Mcap CMP
`)
(`
(`
` bn)
PI Industries
Rallis
August 25, 2014
60
46
` mn)
Net Sales (`
FY15E
FY16E
19,094
20,373
TP Upside
` ) (%)
(`
439 523
238 231
19
(3)
23,404
23,797
FY14
` mn)
EBIDTA (`
FY15E FY16E
2,890
2,534
3,728
3,118
4,716
3,674
FY14
1,881
1,440
` mn)
PAT (`
FY15E FY16E
2,312
1,768
2,966
2,139
`)
EPS (`
FY14 FY15E FY16E
13.8
7.4
17.0
9.1
21.8
11.0
P/E (x)
ROE (%)
EV/EBITDA(x)
Mcap/Sales (x)
FY14 FY15E FY16E FY14 FY15E FY16E FY14 FY15E FY16E FY14 FY15E FY16E
31.8
32.1
25.8
26.2
20.1 30.7
21.6 21.5
29.1
22.9
28.8
23.7
20.9 16.0 12.3

18.5 15.0 12.6
3.8
2.7
3.1
2.3
2.6
2.0
18
Automobile
DOLAT CAPITAL
India Research
Bajaj Auto (CMP: ` 2263, TP: ` 2420, Mcap: ` 653bn)

z
Bajaj Auto has had a sharp under performance last couple

of quarters (22% vs Nifty 29%) led by concerns on muted
volume growth for its most remunerative models. We believe
these have played out now, and expect the new launches on
Discover to perform well.
Key Assumption
Particulars
FY14 FY15E FY16E
Volume (Lac) 39.22
42.44
48.5
Price
53300
55000 56000
OPM
20.6
20.2
20.8
Earnings Grth
11.1
10
18
With the volume uptick, we also expect significant operating

leverage to play out for Bajaj in the festival season. We expect
volumes to kick in especially in the urban segment as the
sentiment shift on the positive side will drive consumer
spending.
Expect better performance from exports as Egypt market has opened up. Our estimates project
volume growth of 8.2% in FY15 & 14.3% in FY16 with management guiding a early double digit
growth by FY16.
Valuations at 14.9xFY16 are at 15% discount to Hero as against a 3 year average discount of
10-11%.
Balkrishna Industries (CMP: ` 723, TP: ` 776, Mcap: ` 70bn)

z
BKT continues on our preferred picks universe on the back

of strong visibility on volume growth for FY15 and FY16. The
capacity expansion, currently in implementation, shall more
than double its volume through put by FY16 to 300,000 MT.
Given its positioning as a competitive player in the
replacement market in EU and expanding into US, we believe
it is well positioned to capture the space being vacated by
the global tyre manufacturers
Key Assumption
Particulars FY14E FY15E FY16E
Volume (Lakhs) 1.43
1.62
1.93
Price (Lakhs)
2.53
2.58
2.6
OPM (%)
25.0
25.1
25.1
Earnings Grwth 37.3
10.3
26.6
We expect BKT to generate strong operating and free cash

flows as it goes past its capex mode by FY16, and moves
towards reducing debt. Our estimates are building in reduction of debt from 24.5bn to 17.5 bn by
FY17. This shall lead to savings of Rs.140 mn on interest costs in FY 17 as well as drive re rating
over the medium term.
Currency volatility and rise in competitive intensity leading to price under cutting remain risks to
our positive stance.
Valuations at 10.3xFY16 remain attractive for the business generating mid teens operating
margins, and return on equity.
Sr. Analyst:
Kunal Dalal
August
25, 2014
Tel : +9122 4096 9749

19
DOLAT CAPITAL
Automobile - Annual Estimates
India Research
` mn)
Net Sales (`
FY14
FY15E
FY16E
Companies
Auto
Bajaj Auto
Hero Moto Corp
Maruti Suzuki
Tata Motors
201,583
223,967 259,449 41,552 45,249 54,086
252,755
277,621 308,196 35,401 41,589 49,221
444,506
498,282 566,342 52,035 57,801 66,828
2,328,337 2,590,546 2,935,577 348,378 383,401 443,272
Auto Ancilary
Amara Raja
Balkrishna Ind
Suprajit Ind
Companies
` mn)
EBIDTA (`
FY14
FY15E
FY16E
34,367
35,767
5,452
Mcap
` bn)
(`
CMP
`)
(`
43,058
41,336
6,552
48,635
49,728
7,938
TP Upside
` ) (%)
(`
5,564
8,938
931
7,126
10,389
1,068
P/E (x)
FY14 FY15E FY16E
` mn)
PAT (`
FY14
FY15E FY16E
33,803 37,216
21,091 24,486
28,525 33,955
139,911 163,481
8,219
12,503
1,286
3,674
4,884
499
7
3
(2)
4
19.1
24.0
29.0
11.9
17.5 14.9
20.7 17.5
24.4 20.3
10.2
8.6
39
40
14
27
35
41
15
22
34
41
17
21
Auto Ancilary
Amara Raja
Balkrishna Ind
Suprajit Indu
(3)
7
6
25.8 21.6 18.6

14.3 13.0 10.3
27.4 21.5 17.7
30
29
26.9
28
25
27.7
26
25
27.0
August 25, 2014
555
723
114
538
776
121
43,763 117.9 128.6 151.2

29,028 105.6 122.6 145.4
40,651 94.5 112.4 134.6
192,546 43.5 50.8 59.8
5,106
6,815
774
21.5
50.5
4.2
25.7
55.7
5.3
29.9
70.5
6.5
ROE (%)
EV/EBITDA(x)
Mcap/Sales (x)
FY14 FY15E FY16E FY14 FY15E FY16E FY14 FY15E FY16E
Auto
Bajaj Auto
653 2,263 2420
Hero Moto Corp 507 2,538 2616
Maruti Suzuki
827 2,739 2692
Tata Motors
1,390
516 538
95
70
14
4,384
5,389
637
`)
EPS (`
FY14 FY15E FY16E
15.6 13.8 11.2

14.4 12.3 10.4
16.2 14.4 12.2
6.1
5.6
4.8
3.2
2.0
1.9
0.7
2.9
1.8
1.7
0.6
2.5
1.6
1.5
0.6
16.7
10.5
16.3
2.8
2.0
2.5
2.2
1.7
2.1
1.9
1.4
1.7
13.1
9.1
14.2
11.1
7.2
11.7
20
Capital Goods
DOLAT CAPITAL
India Research
Crompton Greaves (CMP: ` 202, TP: ` 240, Mcap: ` 130bn)

z
We believe, Crompton is at the end of the tunnel for its

international business as the margin recovery appears to be
more realistic than few quarters back. Improved realisation/
order book coupled with restructured operations would drive
the margins from Q3FY15 onwards.
Key Assumption
Particulars
FY14 FY15E FY16E
Revenue Gr
11.5
11.0
11.2
EBITDA Gr
78.0
44.2
40.5
5.1
6.6
8.3
188.9
92.0
66.9
OPM
z
We expect the international subsidiaries to be PAT positive

in FY16E.
Domestic business would also stand to benefit from the

expected recovery in the capex cycle for both its Power and
Industrial business
The companys plans to demerge its consumer business provides substantial value unlocking
benefit to investors. Overall valuations also remain comfortable to provide reasonable upside
from current levels.
PAT Gr
Larsen & Toubro (CMP: ` 1541, TP: ` 1694, Mcap: ` 1428bn)

z
L&T would be the key beneficiary of the recovery in

infrastructure spend in the country. The company has made
investments in sectors like defence & power, which should
stand to benefit with the efforts of the new government to
step up domestic manufacturing in these areas.
Key Assumption
Particulars
FY14 FY15E FY16E
Revenue Gr
14.3
14.4
18.3
EBITDA Gr
9.1
-2.2
28.3
OPM
12.6
16.8
11.7
PAT Gr
-4.7
1.9
39.6
We believe the company is well placed to grow its

international order inflow in the Middle-east region. The has
already bagged some marquee projects in this region and
we expect the order flow momentum from this region to
continue going ahead.
L&Ts investment into its developmental arm has been a drag on its cash flows and return ratios.
The companys plans to unlock value from the same augurs well for the standalone EPC business.
Post the recent correction, valuations are now reasonable and provides reasonable upsides
from current levels.
Sr. Analyst:
Pawan Parakh
August
25, 2014
Tel : +9122 4096 9712

Associate: Avinash Kumar

Tel: +9122 40969764
21
DOLAT CAPITAL
Capital Goods - Annual Estimates
India Research
FY14
` mn)
PAT (`
FY15E FY16E
391,088 328,933 338,233 45,198 32,906 34,759 34,607

134,806 149,618 166,404
6,820
9,833 13,814
2,443
42,475 47,982
57,135
7,099
8,062 10,164
6,000
18,844 18,992
22,535
3,793
3,280
5,017
4,825
851,284 973,733 1,151,687 107,543 105,129 134,916 45,680
50,999 54,008
60,249
4,373
4,449
5,588
2,460
5,057
6,794
8,354
1,038
1,500
1,936
684
52,660 58,984
65,836
2,656
3,651
5,029
2,454
24,132 25,331
4,691
7,830
7,034
7,853
4,418
5,674
46,547 64,970
2,628
3,510
983
1,292
2,749
3,768
Companies
FY14
BHEL
Crompton - Cons
Cummins
Engineers India
L&T - Cons
Thermax
Triveni Turbine
Voltas
Companies
Mcap
(`
` bn)
` mn)
Net Sales (`
FY15E
FY16E
CMP
`)
(`
TP Upside
` ) (%)
(`
BHEL
556
227 200
Crompton - Cons 130
202 240
Cummins
188
679 565
Engineers India
80
238 300
L&T - Cons
1,428 1,541 1,694
Thermax
106
890 674
Triveni Turbine
30
90
98
Voltas
66
200 225
August 25, 2014
(12)
19
(17)
26
10
(24)
8
13
` mn)
EBIDTA (`
FY14
FY15E FY16E
`)
EPS (`
FY14 FY15E FY16E
14.1
3.9
21.6
14.3
49.3
20.6
2.1
7.4
9.9
7.5
25.4
13.1
50.2
22.1
3.0
8.3
10.3
12.5
28.3
16.8
70.1
29.5
3.9
11.4
P/E (x)
FY14 FY15E FY16E
ROE (%)
EV/EBITDA(x)
Mcap/Sales (x)
16.1
51.8
31.4
16.6
31.3
43.1
43.6
27.0
10.9
6.8
24.2
20.5
12.8
12.6
42.1
13.0
23.0
27.0
26.8
18.2
30.7
40.4
30.3
24.1
21.9
16.2
24.0
14.1
22.0
30.2
23.1
17.6
7.1
12.3
22.9
17.5
11.9
12.4
45.5
14.3
7.1
18.1
25.9
21.0
15.2
15.1
43.6
17.2
9.3
21.0
26.4
14.6
20.1
25.2
28.8
22.6
11.8
15.1
23.1
19.5
21.1
23.2
19.3
16.3
10.7
10.9
18.4
12.3
17.5
18.9
14.3
11.5
1.4
1.0
4.4
4.3
1.7
2.1
5.9
1.3
1.7
0.9
3.9
4.2
1.5
2.0
4.4
1.1
1.6
0.8
3.3
3.6
1.2
1.8
3.6
1.0
22
Cement
DOLAT CAPITAL
India Research
JK Lakshmi Cement (CMP: ` 305, TP: ` 309, Mcap: ` 36bn)

z
JKLCs volume expansion is timing well with the likely demand

revival next few quarters. This, coupled with the entry into
lucrative Eastern India segment, will help realisations and
margins stay elevated.
Key Assumption
Particulars
FY14 FY15E FY16E
Volume (Mt)
5.6
6.5
7.6
Price (Rs/t)
3666
3904
4197
Cumulative capacity at 11.4 mt (including Udaipur Cement)

OPM
14.7
16.4
19.0
will place it as a meaningful mid size players with well spread
PAT Grw(%)
-42
24
54
presence across North, East and Western belts. While
competition in these areas is also strong, we believe JKLC
has the brand push to stand its ground. Notably, the new
capacity additions are coming up in Eastern belt which is relatively better off on realisations and
margins.
Potential for increasing the share of trade sales will help margins structurally. We estimate a 1%
rise in realisation to increase EBIDTA/tonne by 4%.
Our volume estimates for FY15 and FY16 are 6.46Mt and 7.61Mt respectively.
Ultratech Cement (CMP: ` 2651, TP: ` 2851, Mcap: ` 723bn)

z
Our preferred large cap cement play and proxy for the India
economy revival. Capacity additions over the last few years
have placed it strongly in the key markets with high brand
recall and distribution.
Key Assumption
We estimate Ultratech to register 10.8% CAGR in volumes

FY14-16E, and realisations to register 4.9% CAGR during
the same period of FY16-16E

Volume
42
46.6
51.6
Price
4780
5004
5260
OPM
18.0
19.9
21.4
-19.1
21.0
26.0
PAT Grwth
Our base case estimates EBIDTA per tonne to grow at a

CAGR of 14.4% during FY14-16E. We expect UTCEM to
clock an EBITDA/ton of Rs1127 in FY16E on account of
improved demand and pricing environment.
Head of25,
Research:
August
2014 Amit Khurana
Tel : +9122 4096 9745
Associate: Manish Raj

Tel : +9122 4096 9754
23
DOLAT CAPITAL
Cement - Annual Estimates
India Research
` mn)
Net Sales (`
FY14
FY15E
FY16E
Companies
200,779
20,566
UTCEM
JKLC
Companies
Mcap
(`
` bn)
UTCEM
JKLC
August 25, 2014
CMP
`)
(`
233,190
25,210
TP Upside
` ) (%)
(`
723 2,651 2,851

36
305
271,412
31,925
309
` mn)
EBIT (`
FY14
FY15E
FY16E
36,160
3,020
46,291
4,130
` mn)
PAT (`
FY14
FY15E FY16E
58,177 21,445
6,065
1,115
26,018 32,888
1,385
213
`)
EPS (`
FY14 FY15E FY16E
75.6
9.5
94.9 119.9
11.8 18.1
P/E (x)
FY14 FY15E FY16E
ROE (%)
EV/EBITDA(x)
Mcap/Sales (x)
30.3
24.1
16.1
12.8
14.3 15.8
16.2
12.8 10.3
0.4
0.3
0.3
32.2
25.9
16.8
9.0
10.5 14.5
15.9
12.4
1.7
1.4
1.1
8.2
24
Consumer
DOLAT CAPITAL
India Research
Pidilite Industries (CMP: ` 386, TP: ` 417, Mcap: ` 202bn)

z
Pidilite recovered strongly from the disappointing

performance in Q4FY14. The rebound in Q1FY15 reinforces
our positive structural stance, hence it continues in our
preferred picks universe. Operating performance will also
improve as full effect on price increase plays out from
Q3FY15.
Portfolio continues to be strongly placed with construction
chemical continues to grow on a faster pace. We expect
revenue growth across categories to remain strong as the
Key Assumption
Particulars
FY14 FY15E FY16E
Revenue grth
16.4
16.7
17.4
Const/chem grth 15.0
20.0
20.0
OPM
15.8
16.0
16.4
24
24
Earnings
economy turnaround works its way. Pricing power remains intact as well.
z
International operations showed significant improvement after a protracted under performance.

We believe this is sustainable.
We estimate a 17% CAGR in revenue and 24% CAGR in PAT. The stock trades at 34x FY15E
and 27x FY16E.
Relaxo Footwear (CMP: ` 400, TP: ` 450, Mcap: ` 24bn)

z
Relaxo is one of our favourites to play on Indian consumption

theme. We believe that the footwear industry is at the cusp
of moving from unorganised to organised (branded), and
Relaxo is amongst the best positioned to leverage on the
same.
Key Assumption
Particulars (%)
Volume Grth
Realisation Grth
OPM
FY14 FY15E FY16E

8
12
11
11
12.1
12.3
12.5
It has also refurbished its portfolio across price points and

Earnings
46
33
32
ventured into sports shoes. With a strong brand like Sparx, it
is expanding its reach to South and West market. The company has got good consumer
acceptance for its sport shoe product.
We expect volume growth of mid to high single digits and product mix change to sustain growth
our base case remains of 18-20% CAGR in revenue and this may improves as the companys
new products continue to expand their reach.
Valuations at 27x FY15E and 20x FY16E are not as cheap as we would have desired for an
entry perspective. However, we believe one will be adequately compensated through structural
outperformance at an absolute level and not just relative.
Sr. Analyst:
Amit Purohit
August
25, 2014
Tel : +9122 4096 9724

25
Consumer
India Research
DOLAT CAPITAL
Whirlpool of India (CMP: ` 441, TP: ` 483, Mcap: ` 58bn)

z
Remains one our preferred plays on the discretionary

consumption pick up. With urban sentiment turning even
better, we believe Whirlpool shall be one of the best
positioned on volume recovery. Further, the competition has
become more rational.
Key Assumption
Particulars
FY14 FY15E FY16E
Volume
-4.5
11.0
11.0
Price
6.4
8.7
7.0
OPM
7.4
9.9
10.6
The company has been increasing its focus on distribution

as it aggressively adds dealers (currently stands at 1618000). It has increased its focus towards premium products
in each of the product segments. It has gained market share
in the premium segment of each category.
With a focus on profitability rather than market share, we believe the company would get the
benefit of operating leverage as volumes at the Industry level improves.
For FY14, volume decline by 4.5% while Q1YFY15, witnessed a revival in growth as volumes
grew by 7% during the quarter.
We estimate 18% CAGR in revenues during FY14-16E and earnings to register 51% CAGR in
the same period. The stock trades at 27x FY15E EPS of ` 16.3 and 19.8x FY16E EPS of ` 22.
August 25, 2014
26
DOLAT CAPITAL
Consumer - Annual Estimates
India Research
Companies
FY14
Asian Paints
Berger Paints
Dabur
HUL
ITC
Page Ind
Pidilite Ind
Relaxo Footwear
Titan Ind
Whirlpool India
Companies
` mn)
Net Sales (`
FY15E
FY16E
127,148
38,417
70,804
280,191
332,386
11,732
42,832
12,120
109,274
28,331
Mcap
` bn)
(`
CMP
`)
(`
146,280
44,146
82,502
320,241
383,415
14,658
50,344
14,664
125,358
33,173
August 25, 2014
` mn)
EBIDTA (`
FY15E
FY16E
FY14
` mn)
`)
PAT (`
EPS (`
FY15E FY16E FY14 FY15E FY16E
170,581 19,979 23,624 27,741 12,288 15,349 18,257 12.8 16.0 19.0
50,753
4,236
5,053
6,017
2,432
3,079
3,692
7.0
8.9 10.7
95,680 11,416 13,936 16,517
9,139 10,889 13,031
5.2
6.2
7.5
366,515 44,753 53,525 62,793 35,527 41,615 47,958 16.4 18.9 21.2
443,424 124,549 144,249 168,823 87,852 101,564 119,977 10.8 12.8 15.1
18,488
2,366
3,014
3,878
1,537
1,952
2,508 137.8 175.0 224.8
59,250
6,770
8,053
9,689
4,619
5,731
7,103
9.0 11.2 13.9
17,652
1,465
1,798
2,203
656
872
1,155 11.0 14.5 19.2
146,437 10,443 12,597 15,296
7,348
8,631 10,969
8.3
9.7 12.4
39,508
2,100
3,288
4,179
1,229
2,064
2,788
9.7 16.3 22.0
TP Upside
` ) (%)
(`
Asian Paints
581
616 590
Berger Paints
119
344 330
Dabur
392
222 225
HUL
1,555
708 742
ITC
2,783
343 345
Page Ind
83 7,440 6,745
Pidilite Ind
202
386 417
Relaxo Footwear 24
400 450
Titan Ind
321
363 345
Whirlpool India
58
441 483
FY14
(4)
(4)
1
5
1
(9)
8
13
(5)
10
P/E (x)
FY14 FY15E FY16E
ROE (%)
EV/EBITDA(x)
Mcap/Sales (x)
48.1
49.1
42.7
43.2
31.8
54.0
42.8
36.4
43.9
45.5
33.0
23.0
38.0
111.0
36.1
61.2
24.3
24.0
32.8
16.6
38.5
38.7
35.8
37.5
26.9
42.5
34.4
27.6
37.4
27.1
32.4
32.1
29.6
33.4
22.7
33.1
27.7
20.8
29.4
20.1
34.0
25.0
37.0
94.0
37.3
58.1
25.1
24.0
30.4
21.8
34.0
25.0
37.0
81.0
38.6
56.4
25.7
25.0
30.9
22.8
23.6
21.0
29.2
26.1
20.4
36.0
27.0
17.4
31.0
25.3
19.5
17.4
23.6
22.4
17.4
28.0
23.0
14.1
25.4
15.8
16.2
14.4
20.0
19.2
14.6
22.0
19.0
11.3
20.4
11.8
3.8
2.3
4.7
4.4
8.0
7.0
4.4
1.9
2.9
2.0
3.3
2.0
4.0
3.9
7.0
5.7
3.8
1.6
2.6
1.7
2.8
1.7
3.5
3.4
6.0
4.6
3.2
1.3
2.2
1.4
27
Int
en
tio
na
lly
Le
ft B
lan
k
India Research
DOLAT CAPITAL
August 25, 2014
28
Energy
India Research
DOLAT CAPITAL
Gulf Oil Corporation (CMP: ` 276,TP: ` 333,Mcap: ` 13.8bn)

z
Post demerger of Gulf Oil into Lubricants and Non Lubricants,

Gulf Oil Lubricants has emerged as pure play with significant
potential to grow. We expect it to grow at 2x the industry
growth rate, driven by the expanding distribution network and
increasing penetration across product categories.
Key Assumption
Particulars
FY14 FY15E FY16E
EBIT Margin
13.2
13.0
13.5
PAT Margin
4.4
14.0
We believe it can maintain operating margins above 12%

(currently 12.9%). Balance sheet becomes light as there is
no long term debt. Net debt for working capital requirements
is at ` 800 mn.
Royalty issue is clarified that it will remain at current levels. Dividend is expect to remain at
current levels of 40% and can move upwards.
Capacity expansion at Silvasa and Chennai plant to be funded through internal accruals only.
Post completion of Silvasa plant, the capacity of Gulf Oil will increase to 95,000 KL as compared
to existing 75,000 KL.
We feel that GOLIL can do earnings of Rs 832 mn in FY16E. The stock trades at 16.2x FY16E
earnings. We have a BUY recommendation with a target price of ` 333 to trade at 20x FY16E
earnings.
Analyst:25,
Priyank
August
2014Chandra
Tel : +9122 4096 9737

29
DOLAT CAPITAL
Energy - Annual Estimates
India Research
` mn)
Net Sales (`
FY15E
FY16E
FY14
39,174 43,733 50,317

31,429 35,247 38,951
9,439
9,936 10,758
31,796 33,052 34,718
417,758 425,654 445,879
7,824
5,677
8,324
6,877
14,587
Companies
FY14
Indraprastha Gas
Gujarat Gas
GSPL
Castrol India
Petronet LNG
Companies
Indraprastha Gas
Gujarat Gas
GSPL
Castrol India
Petronet LNG
August 25, 2014
Mcap CMP
`)
(`
` bn) (`
52
59
50
171
133
371
462
88
358
177
TP Upside
` ) (%)
(`
388
342
74
327
144
5
(26)
(16)
(9)
(19)
` mn)
EBIDTA (`
FY15E
FY16E
8,902
6,992
8,710
7,007
16,458
10,167
6,671
9,471
7,742
18,758
FY14
3,604
3,734
3,848
5,087
6,978
` mn)
PAT (`
FY15E FY16E
4,169
4,383
3,990
4,911
6,687
4,531
4,584
4,506
5,412
9,100
P/E (x)
ROE (%)
EV/EBITDA(x)
14.4
15.9
13.0
34.8
19.0
12.5
14.5
12.4
36.0
19.9
11.5
13.5
11.0
32.7
14.6
22.1
34.5
19.8
72.6
15.4
21.7
32.1
17.8
73.2
15.2
20.2
31.8
17.1
86.0
17.4
7.6
6.7
5.5
11.5
9.7
9.2
6.5
6.1
5.8
24.0 23.6 21.1
7.3
6.5
6.1
`)
EPS (`
FY14 FY15E FY16E
25.7
29.1
6.8
10.3
9.3
29.8
31.8
7.1
9.9
8.9
32.4
34.2
8.0
10.9
12.1
Mcap/Sales (x)
FY14 FY15E FY16E
1.3
1.9
5.3
5.4
0.3
1.2
1.7
5.0
5.2
0.3
1.0
1.5
4.6
4.9
0.3
30
Financial
DOLAT CAPITAL
India Research
Axis Bank (CMP: ` 402, TP: ` 455, Mcap: ` 949bn)

z
The bank is still adopting a cautious growth strategy over the

next couple of quarters and an improvement in the balance
sheet growth is likely to be back-ended in FY15.
Asset quality should remain under control and we believe
that despite having reasonable exposure to the infrastructure
segment the bank has done well in keeping its stressed
assets pool at 3.8%. While the management has continued
with its guidance of higher stress levels, we believe that
additions to the stressed assets pool are unlikely to be
alarming.
Growth (%)
FY14 FY15E FY16E
NII
24
16
19
PPOP
23
12
19
PAT
20
13
22
Loans
17
20
22
Deposits
11
18
21
NIM (%)
3.8
3.8
3.9
GNPL (%)
1.2
1.2
1.1
As the investment cycle and money flow within the economy improves, the bank can see a
reasonable amount of deflation in its stressed assets pool. However, this is unlikely to be
immediate and can take some time to pan out.
Current valuations of 2.1x FY15E ABVPS forecasts still provides reasonable room for further
upsides as the bank is well placed to capitalize on the change in the economic cycle. We maintain
our preference for Axis Bank in our top picks with a target price of Rs 455 based on PABR of
2.5x on FY15 ABVPS forecasts.
Bank of Baroda (CMP: ` 920, TP: ` 1,070, Mcap: ` 387bn)

z
Our preference for BOB continues on its relatively better than

industry book quality, and lower restructuring pipeline. This
has also helped BOB to deliver stable operating performance
of late.
Growth (%)
FY14 FY15E FY16E
NII
21
23
PPOP
21
21
PAT
23
24
NPL recoveries have helped further to deliver better earnings

trajectory and coupled with the upgrades, have kept the gross
NPL levels under control.
Loans
21
22
24
Deposits
20
19
21
NIM (%)
2.0
2.1
2.1
The total stressed assets at 9% looks moderate due to the

low stress in the overseas operations. Domestic stressed
GNPL (%)
2.9
3.0
2.8
assets at 11.6% is also better than many of its PSB peers. We expect stressed assets to remain
at the current levels before they start trending lower.
z
The bank has shown extremely strong recoveries, in a quarter when the NPL recoveries have
tended to be lack luster for most of its peers. If the bank is able to maintain the pace of recoveries
and upgrades, we expect another re-rating from the current valuations of 1.2x on FY15 ABVPs
forecasts.
Sr. Analyst:
Rajiv Pathak
August
25, 2014
Tel : +9122 4096 9750

Associate: Pranav Joshi

Tel : +9122 4096 9706
31
Financial
India Research
DOLAT CAPITAL
City Union Bank (CMP: ` 78, TP: ` 85, Mcap: ` 47bn)

z
CUBs focus on core semi metro areas and business and

retail loans continues to aid sustenance of higher than sector
yields. With the environment turning for the better and
business activity expected to pick up, we expect CUB growth
trajectory to accelerate. The recent equity raising (USD 58
mn, 9% dilution on existing equity) shall enable it to be
adequately funded for at least couple of years.
Growth (%)
FY14 FY15E FY16E
NII
22
14
22
PPOP
11
11
26
PAT
15
26
Loans
15
23
Deposits
16
22
NIM (%)
3.3
3.3
3.4
GNPL (%)
1.8
2.0
1.8
Resumption of growth and improvement in NIMs should drive

the earnings growth over the next two years.
Despite the rise in the NPLs that we built in for FY15, gross NPLs at 2% would still be amongst
the best in industry. We believe that with the recognition of these accounts, a bulk of the potential
stressed accounts are now recognized and dealt with. Asset quality focus has been the
differentiating factor for CUB to sustain well even in the most difficult of times, and we expect
this parameter to hold well.
We believe that the bank which has seen a phase of low balance sheet growth should resume
the growth trajectory in 2HFY15 and asset quality pressures would start to abate. ROEs which
look subdued due to both the capital raise and the low growth should see an improvement and
should be closer to 20% by FY16. Valuations at 1.8x on FY15 ABVPS forecasts is attractive
ICICI Bank (CMP: ` 1538, TP: ` 1730, Mcap: ` 1779bn)

z
Our top pick in the private banks, as it returns to its growth

focus coupled with a reduction in the incremental asset quality
stress. We also feel comforted by the stable stressed assets
at 6.2% and decline in delinquency rates from 3.9% in
Q4FY14 to 2.9%.
The bank has an outstanding foreign currency translation
reserve from the profits of its overseas subsidiaries to the
tune of 20bn, which it plans to drawdown on a regular basis,
aiding the profitability.
Growth (%)
FY14 FY15E FY16E
NII
19
11
20
PPOP
26
18
PAT
18
20
Loans
17
18
21
Deposits
13
14
16
NIM (%)
3.1
3.1
3.2
GNPL (%)
3.0
2.9
2.7
The bank continued to maintain its stable growth and asset quality trend. We believe that
comfortable capital adequacy; option of repatriating profits from overseas, lower incremental
stress on asset quality and improvement in growth momentum in 2HFY15 bodes well for the
bank to improve its earnings, return ratios and the valuations.
Valuations for the core bank at 2x on FY15 Banking ABVPS attractive. Our SOTP places the
target multiple at 2.5x on FY15 Banking ABVPS and other businesses at 320 p/s
August 25, 2014
32
Financial
India Research
DOLAT CAPITAL
`348bn)
Punjab National Bank (CMP: `984,TP: `1,150,Mcap:`
z
We have had a preference for PNB on our belief that it will

be one of the biggest beneficiaries of economic turnaround
and softening yields over next few quarters. Notably, the
quarterly earnings have also shown up a reduction in fresh
NPL formations as well as additions to restructured loans
adding to our conviction.
We also expect the NIM (3.42% for Q1) to sustain an upward
trajectory on lower delinquencies and moderate reduction in
cost of deposits over the next two years.
Growth (%)
FY14 FY15E FY16E
NII
11
18
PPOP
19
(30)
37
35
Loans
13
17
20
Deposits
15
16
19
NIM (%)
3.2
3.1
3.2
GNPL (%)
5.3
5.4
4.7
PAT
Management commentary on growth focus being on agenda, and with requisite systems in place
will help PNB to emerge well, and lead the PSU pack.
Near term overhang remains on fresh equity issue likely in H2FY15.
Valuation at 1.2x on FY15 ABVPS attractive.
PTC India Financial (CMP: ` 43, TP: ` 54, Mcap: ` 24bn)

z
PTC India Financial Services (PFS) is one of the latest

entrants to our preferred picks universe. Our arguments for
liking this mid-sized diversified lender to power sector is
based on it being well set to leverage upon the growth
opportunities in the renewable energy segment, especially
solar power. The loan book which had quadrupled in the past
couple of years can potentially triple from its current size in
the next couple of years driven by the opportunities in the
renewable segment, where the company has a forte.
Growth (%)
FY14 FY15E FY16E
NII
41
79
69
PPOP
88
63
36
PAT
99
45
33
Loans
117
75
72
Borrowings
145
85
80
NIM (%)
6.8
5.5
5.4
GNPL (%)
0.1
1.2
1.7
Renewable energy, especially solar power is gaining favor from the new government as well as
turned cost competitive since last few years. Hence we believe it has the potential to turn into a
meaningful growth segment next few years. This, we believe, places PFS in a sweet spot given
its technical competence to evaluate such projects, and well capitalized balance sheet to sustain
growth over next few years.
Current low leverage makes the ROE look subdued. However as the company leverages on the
growth opportunities, ROEs should improve to 23% from 16% currently. High growth potential
coupled with low stressed assets pool and improving return ratios makes us positive on the
stock. Valuations of 1.2x on FY15E ABVPS are attractive.
August 25, 2014
33
Financial
India Research
DOLAT CAPITAL
Yes Bank (CMP: ` 584, TP: ` 673, Mcap: ` 242bn)

z
One of the best positioned mid size banking plays to leverage

upon the economic upturn. Recent fund raising capitalises it
for next couple of years, and enables to press the accelerator
on growth. It has had a more cautious approach last few
quarters on that front.
Biggest beneficiary of the softening of rates over 12-18
months
Growth (%)
FY14 FY15E FY16E
NII
22
24
22
PPOP
26
28
24
PAT
24
27
25
Loans
18
23
25
Deposits
11
21
23
NIM (%)
2.8
3.0
3.1
GNPL (%)
0.3
0.4
0.6
Ability to sustain 20% plus return on equity remains a key

valuation support, and return to 25% earnings CAGR over
FY14-16E.
Our assumptions are guided a strong growth in corporate book next few quarters, in line with the
economic trajectory on the up move.
Valuations at 1.9x on FY15 AVPS forecasts is attractive and well below its long term average.
August 25, 2014
34
DOLAT CAPITAL
Financials - Annual Estimates
India Research
Companies
FY14
Axis Bank
Bank of Baroda
Bank of India
City Union Bank
HDFC Bank
ICICI Bank
ING Vysya Bank
Karur Vysya Bank
Punjab National Bank
State Bank of India
Union Bank
Yes Bank
Companies
Mcap
(`
` bn)
119,516
119,653
108,304
7,594
184,826
164,756
17,532
12,837
161,460
492,822
78,793
27,163
CMP
`)
(`
` mn)
NII (`
FY15E
FY16E
138,279
144,667
136,046
8,676
216,444
182,723
19,770
15,507
178,476
591,734
87,816
33,725
114,561
92,910
84,228
5,810
143,601
165,947
11,275
8,378
113,847
321,092
52,181
26,880
128,771
112,216
105,597
6,470
174,282
180,594
13,635
10,840
124,026
385,760
56,480
34,501
153,280
136,262
124,491
8,150
215,219
213,551
16,702
13,728
146,988
457,188
64,850
42,635
FY14
13
16
23
8
4
13
13
18
17
13
13
15
17.4
13.8
11.2
18.3
21.3
17.0
10.3
13.4
10.2
10.0
10.4
25.0
17.1
15.0
12.8
16.9
21.0
16.4
10.8
16.1
12.6
11.9
11.0
21.7
18.2
16.3
15.9
17.3
22.1
17.5
12.5
17.6
15.2
14.8
12.8
20.0
1.7
0.8
0.5
1.4
1.9
1.7
1.1
0.9
0.7
0.6
0.5
1.6
1.7
0.8
0.6
1.5
1.9
1.7
1.2
1.1
0.8
0.8
0.5
1.7
` mn)
`)
PAT (`
EPS (`
FY15E FY16E FY14 FY15E FY16E
62,177 70,213 85,853

45,411 55,732 69,252
27,292 35,220 49,254
3,471
3,981
5,012
84,784 99,472 124,440
98,106 106,652 127,996
6,579
7,857 10,068
4,296
6,163
8,123
33,426 45,913 61,784
108,912 148,112 205,355
16,962 19,191 24,304
16,178 20,473 25,670
TP Upside
ROE (%)
ROA (%)
` ) (%)
(`
FY14 FY15E FY16E FY14 FY15E FY16E
Axis Bank
949 402 455
Bank of Baroda
387 920 1,070
Bank of India
174 292 360
City Union Bank
47
78
85
HDFC Bank
2,041 847 880
ICICI Bank
1,779 1,538 1,730
ING Vysya Bank
122 640 720
Karur Vysya Bank 51 482 570
Pun. Nat. Bank
348 984 1,150
State Bk of India 1,884 2,524 2,858
Union Bank
132 221 250
Yes Bank
242 584 673
August 25, 2014
164,765
177,301
161,765
10,581
265,554
219,215
23,577
19,589
211,299
713,607
102,996
41,080
` mn)
Operating Income (`
FY14
FY15E
FY16E
1.8
0.8
0.7
1.6
2.0
1.8
1.4
1.2
0.9
0.9
0.6
1.8
26
106
42
6.4
35
85
35
40
92
152
27
45
30
129
55
6.8
41
92
42
51
127
198
30
49
37
161
77
8.5
52
111
53
67
171
275
39
62
P/E(x)
P/ABV (x)
15.2
8.6
6.9
12.2
24.0
14.4
18.4
12.0
10.7
12.5
8.2
13.0
13.5 11.0
7.1
5.7
5.3
3.8
11.6
9.2
20.4 16.3
13.2 11.0
15.4 12.0
9.4
7.2
7.8
5.8
9.6
6.9
7.2
5.7
11.8
9.4
2.54
1.37
1.00
2.33
4.77
2.44
1.76
1.62
1.45
1.80
1.20
2.97
2.22
1.23
0.89
1.88
4.03
2.16
1.63
1.41
1.29
1.79
1.08
2.07
1.92
1.05
0.76
1.61
3.38
1.91
1.45
1.26
1.09
1.52
0.94
1.75
35
Int
en
tio
na
lly
Le
ft B
lan
k
India Research
DOLAT CAPITAL
August 25, 2014
36
IT Services
DOLAT CAPITAL
India Research
KPIT Technologies (CMP: ` 150, TP: ` 190 , Mcap: ` 30bn)

z
We are including KPIT in our preferred picks universe as we

believe the weak Q1 has set the floor on margins and stock
performance. We are in sync with the management view that
the weak result was a function of poor execution rather than
any challenges on the business momentum.
Key Assumption
Particulars
Volume
Price Growth
OPM
FY14 FY15E FY16E

9
(1)
14
(2)
14
0
13.5
13.5
14.1
EPS growth
28.7
15.9
11.3
Our estimates of 11% revenue growth though below the
management guided range ($ rev growth 12-14%), still offers
strong upside potential hereon. Recovery in SAP sbu would mean better earnings growth ahead
of revenue growth.
Focused approach on its niche strength (Automotive, Enterprise services and recovery in SAP
SBU (OPM turned positive) remain core to our preference. KPIT is also well positioned to benefit
from incremental role of IT in Automobile.Valuations at 9x FY16E (4.5x EV/EBIT) remain attractive.
Mphasis (CMP: ` 440, TP: ` 580, Mcap: ` 92bn)

z
Mphasis has been one of the quite outperformers in the IT

services since last six months.
Key Assumption
We believe our primary argument to include in the preferred

picks universe holds ground, and more so now. We expect
HP share of revenues to keep getting diluted, and the non
HP to gain traction helping generate better operating margins
Volume (%)
14
Price Growth
HP Rev share
OPM
39
15
34
15.4
31
17.2
EPS Growth
(2)
5.4
27.4
Particulars
FY14 FY15E FY16E
Our estimates are based on a 11% growth for the non HP

revenues over FY14-FY16E, and HP contracting by 4% over
the same period
Valuations at 9x FY16E (4.7x EV/EBIT) remain cheap, and with limited downsides. Adjusted for
cash, Mphasis is one of the cheapest IT stocks with 4% on dividend yield
Sr. Analyst:
Rahul Jain
August
28, 2014
Tel : +9122 4096 9754

37
DOLAT CAPITAL
IT Servies - Annual Estimates
India Research
Companies
FY14
Eclerx
HCL Tech
Infosys
KPIT Technologies
Mindtree
Mphasis
NIIT Tech
Nucleus
OFSS
Persistent
TCS
Tech mahindra
Wipro
` mn)
Net Sales (`
FY15
FY16E
8,410
329,180
501,330
26,940
30,316
25,939
23,050
3,499
37,413
16,692
818,094
188,313
434,269
Companies
Mcap
(`
` bn)
CMP
`)
(`
Eclerx
HCL Tech
Infosys
KPIT Tech
Mindtree
Mphasis
NIIT Tech
Nucleus
OFSS
Persistent
TCS
Tech Mahindra
Wipro
37
1091
2052
28
88
92
22
7
297
50
4824
529
1364
1259
1579
3585
150
1057
440
370
225
3535
1258
2465
2282
554
August 28, 2014
FY14
` mn)
EBIT (`
FY15E
FY16E
9,245
10,825
3,206
3,130
3,594
368,912 426,139 79,350 85,035 98,506
537,019 615,064 120,410 136,661 157,725
29,650
33,652
3,669
4,062
4,889
35,514
41,035
6,100
7,144
8,258
62,087
70,792
3,893
9,548 12,161
24,666
29,197
2,896
3,124
4,007
3,822
4,336
592
662
803
43,356
49,421 13,994 17,571 19,798
18,859
22,123
4,303
4,600
5,506
950,618 1,095,963 238,079 268,278 308,820
213,974 244,728 36,615 38,206 47,388
468,973 516,217 89,354 95,435 105,401
TP Upside
` ) (%)
(`
1200
1750
3875
190
920
585
500
215
4040
1135
2770
2500
555
(5)
11
8
27
(13)
33
35
(4)
14
(10)
12
10
0
FY14
` mn)
PAT (`
FY15E FY16E
`)
EPS (`
FY14 FY15E FY16E
2,557
2,467
2,835 82.8
63,710 70,200 81,730 92.2
106,480 120,220 138,328 186.2
2,489
2,885
3,211 13.4
4,268
5,287
5,919 54.0
3,027
7,660
9,757 14.4
2,305
2,383
3,015 38.5
627
660
778 19.4
13,593 15,380 16,995 161.5
2,791
2,734
3,496 62.3
191,087 217,266 246,490 97.6
30,287 30,079 36,712 127.5
77,529 81,827 90,566 31.7
79.9
101.6
210.2
15.6
60.8
36.5
39.8
20.4
182.8
74.7
111.0
126.3
33.4
91.9
118.3
241.8
17.3
70.8
46.4
50.4
24.0
202.0
87.4
125.9
158.9
37.0
P/E (x)
FY14 FY15E FY16E
ROE (%)
EV/EBITDA(x)
Mcap/Sales (x)
15.2
17.1
19.3
11.2
19.6
12.7
9.6
11.6
21.9
20.2
25.2
17.9
17.5
49.6
37.4
24.4
21.4
28.3
14.5
19.9
17.3
16.8
22.8
40.7
35.2
24.9
15.8
15.5
17.1
9.6
17.4
12.1
9.3
11.0
19.3
16.9
22.2
18.1
16.6
13.7
13.4
14.8
8.7
14.9
9.5
7.3
9.4
17.5
14.4
19.6
14.4
15.0
36.4
31.0
23.5
20.5
27.1
14.6
18.0
16.6
16.1
22.7
36.3
28.9
22.3
33.5
28.4
23.3
18.9
24.1
17.3
19.8
17.2
15.2
22.1
33.1
27.7
21.1
10.1
11.5
14.2
7.3
11.9
7.3
7.3
5.9
15.0
9.6
18.4
12.2
12.9
10.3
10.7
12.5
6.6
10.1
7.1
6.8
5.3
11.9
9.0
16.3
11.7
12.1
9.0
9.3
10.8
5.5
8.8
5.6
5.3
4.4
10.6
7.5
14.2
9.4
10.9
4.3
3.3
4.1
1.0
2.9
1.5
1.0
2.1
8.0
3.0
5.9
2.8
3.1
4.0
3.0
3.8
0.9
2.5
1.5
0.9
1.9
6.9
2.7
5.1
2.5
2.9
3.4
2.6
3.3
0.8
2.2
1.3
0.8
1.7
6.0
2.3
4.4
2.2
2.6
38
Midcap
DOLAT CAPITAL
India Research
Astral Poly Technik (CMP: ` 826, TP: ` 888, Mcap: ` 46bn)

z
Astral Poly has been on our preferred picks universe for over
3 years, probably the longest stint by a stock!
Key Assumption
We expect growth trajectory to be driven by new products

Blaze Master, Bore well column pipes and adhesives.
Exclusivity in Blaze Master will go a long way to establish
Astral as the preferred brand with first mover advantage.
Volume

60,400 69,000 80,000
OPM
14.5
14.7
14.8
EPS Growth
29.7
57.3
37.0
Hosur plant going operational will help gain South India

markets.
Valuations have had a relentless run last few months (stock is up 130% YTD). Hence near term
consolidation will be helpful to sustain outperformance in the medium term
Analyst:25,
Priyank
August
2014Chandra
Tel : +9122 4096 9737

39
DOLAT CAPITAL
Midcap - Annual Estimates
India Research
` mn)
Net Sales (`
FY15E FY16E
FY14
10,732 13,964 17,961

39,120 45,854 49,587
1,557
5,654
Companies
FY14
Astral Poly
Supreme Ind.
Companies
Astral Poly
Supreme Ind.
August 25, 2014
Mcap CMP
`)
(`
` bn) (`
TP Upside
` ) (%)
(`
46 823 888
70 581 512
8
(12)
` mn)
EBIDTA (`
FY15E
FY16E
2,053
6,049
2,658
7,045
FY14
772
3,037
` mn)
PAT (`
FY15E FY16E
1,215
3,250
1,664
4,158
P/E (x)
ROE (%)
EV/EBITDA(x)
FY14 FY15 FY16E FY14 FY15E FY16E FY14 FY15E FY16E
59.9
24.3
38.1
22.7
27.8
17.8
27.9
31.2
32.7
30.4
32.9
31.4
27.1 19.9
12.8 10.5
14.9
9.8
`)
EPS (`
FY14 FY15E FY16E
13.7
23.9
21.6
25.6
29.6
32.7
Mcap/Sales (x)
FY14 FY15E FY16E
4.3
1.8
3.3
1.5
2.6
1.4
40
Pharmaceuticals
DOLAT CAPITAL
India Research
Biocon (CMP: `474, TP: `537, Mcap: `95bn)

Recently, Biocon has corrected sharply by 14.7%, led by
concerns on regional instability in the MENA region.
However, we believe regional instability is a temporary
phasing issue and growth in biopharma revenues to pickup in H2FY15E.
Key Assumption
Biopharma biz. (excl. India formulations) is expected to

maintain growth momentum, led by geographical expansion
of generic rh-insulin and generic insulin glargine.
Biopharma-India biz is showing clear signs of recovery. Moreover, the company is taking steps
for re-organisation of branded formulation verticals and aims at driving synergies around key
anchor brands and optimisation of product portfolio.
Biocon has started ANDA filings in the US market, which is a key initiative for it to move up the
value chain in its small molecule biz.
Particulars
FY14 FY15E FY16E
Revenue grth
15.8
16.5
29.6
EBITDA grth
26.5
17.3
32.0
OPM
23.9
24.1
24.5
Earnings grth
34.8
13.5
27.0
Divis Laboratories (CMP: `1556, TP: `1648, Mcap: `207bn)

Divis has had an impressive outperformance of 19.8% vs
Niftys 3.4% since our last note of 9th June. Our structural
stance remains that it is amongst the best positioned Indian
suppliers to sustain high teens earnings CAGR FY14-16E
financed through internal accruals.
Key Assumption
Key drivers for the above shall be the ramp up in Vizag SEZ
as it has commissioned all production blocks
Carotenoids segment has not done as well though given the

strong vendor presence with the clients.
Return ratios remain health with ROEs in high 20s
Sr. Analyst:
Milind Bhangale
Autust
25, 2014
Tel : +9122 4096 9731

Particulars
FY14 FY15E FY16E
Revenue grth
18.0
19.9
20.3
EBITDA grth
24.5
20.3
20.7
OPM
40.1
40.2
40.3
Earnings grth
28.5
18.5
19.4
41
Pharmaceuticals
India Research
DOLAT CAPITAL
Lupin (CMP: ` 1251, TP: ` 1455, Mcap: ` 560bn)

Lupin also remains on our preferred picks universe as it
continues to surprise positively on earnings and margins
Key Assumption
Management focus on margins has turned even more

aggressive, and continues to be a key valuation driver in our
view.
Revenue Grth
17.1
20.4
16.9
EBITDA Grth
32.3
26.7
21.1
OPM
26.6
28.0
29.0
ANDA Pipeline continues to be impressive with 20+ launches

in the next 12 months and 130 new launches over the next 23 years.
Earnings Grth
37.0
22.6
20.5
Portfolio mix also remains healthy with well diversified contributions from anti diabetes, CVS,
ophthalmology, gastro, women healthcare et al
Lupin continues to look for M&A targets in brands, technology platform and access to emerging
markets.
Autust 25, 2014
Particulars
FY14 FY15E FY16E
42
Pharmaceuticals - Annual Estimates
India Research
Companies
FY14
Aurobindo
Biocon
Cadila Health
Cipla
Divis Labs
Dr. Reddys
Glenmark
GSK Pharma*
Ipca Labs
Lupin
Sun Pharma
Companies
Aurobindo
Biocon
Cadila Health
Cipla
Divis Labs
Dr. Reddys
Glenmark
GSK Pharma*
Ipca Labs
Lupin
Sun Pharma
80,385
28,773
70,601
101,004
25,321
133,586
60,069
25,462
32,818
112,865
160,044
Mcap
` bn)
(`
236
95
251
400
207
481
195
211
94
560
1,775
CMP
`)
(`
811
474
1,226
498
1,556
2,826
719
2,491
743
1,251
857
` mn)
Net Sales (`
FY15E
FY16E
113,616
33,525
83,462
117,184
30,360
157,831
70,652
26,773
36,144
135,925
183,573
127,202
43,441
96,874
136,834
36,542
181,262
82,158
30,010
43,198
158,944
212,541
TP Upside
` ) (%)
(`
845
4
537 13
1,309
7
535
7
1,648
6
2,968
5
769
7
2,166 (13)
648 (13)
1,455 16
893
4
FY14
` mn)
EBIDTA (`
FY15E
FY16E
21,328
6,871
12,001
21,331
10,145
33,217
13,101
5,221
8,106
30,028
71,956
P/E (x)
FY14 FY15E
17.2 17.1
22.9 20.2
31.2 23.4
28.8 25.9
26.7 22.5
22.3 19.2
25.7 21.5
44.3 40.1
17.0 16.7
30.5 24.9
55.4 30.4
22,799
8,063
15,774
23,671
12,205
38,238
15,739
5,908
8,641
38,059
81,999
FY16E
13.4
15.9
18.7
20.5
18.9
17.1
17.8
34.5
13.8
20.6
26.9
28,293
10,643
19,280
28,735
14,726
42,845
18,398
7,162
10,373
46,094
94,624
FY14
13,759
4,138
8,036
13,872
7,733
21,512
7,599
5,019
5,508
18,363
57,218
DOLAT CAPITAL
` mn)
PAT (`
FY15E FY16E
`)
EPS (`
FY14 FY15E FY16E
13,791 17,581 47.2 47.4 60.4

4,697
5,966 20.7 23.5 29.8
10,724 13,401 39.2 52.4 65.5
15,453 19,507 17.3 19.2 24.3
9,164 10,938 58.3 69.0 82.4
25,022 28,047 126.5 147.1 164.9
9,072 10,978 28.0 33.5 40.5
5,262
6,115 56.2 62.1 72.2
5,624
6,814 43.6 44.6 54.0
22,515 27,140 41.0 50.3 60.6
58,444 66,063 15.5 28.2 31.9
ROE (%)
EV/EBITDA(x)
Mcap/Sales (x)
36.0 30.2 29.1 11.1 10.4
8.1
2.6
1.8
1.7
14.5 14.7 16.8 15.1 12.9
9.7
3.6
3.1
2.4
24.3 27.1 27.7 21.6 16.2 13.0
3.3
2.8
2.4
14.6 14.4 15.9 16.2 14.5 11.6
3.7
3.2
2.7
28.0 27.4 27.0 19.6 16.3 13.6
7.9
6.6
5.5
25.8 24.1 22.0 14.5 12.2 10.4
3.6
3.1
2.7
18.0 24.8 24.0 14.0 11.3
9.4
2.7
2.3
2.0
23.6 26.5 31.1 36.6 32.7 27.0
8.4
8.0
7.1
31.4 25.6 25.0 11.7 10.7
8.8
2.9
2.6
2.2
30.9 29.1 27.4 17.8 13.8 11.1
4.8
4.0
3.4
40.9 34.2 30.8 21.9 18.7 15.7 10.1
8.8
7.6
* December year ending
Autust 25, 2014
43
Int
en
tio
na
lly
Le
ft B
lan
k
India Research
DOLAT CAPITAL
Autust 25, 2014
44
Companies
CMP
`)
(`
Target
`)
(`
Upside
(%)
FY14
Agrochemicals
PI Industries
Rallis
60
46
439
238
523
231
19
(3)
15,869
17,466
Auto
Bajaj Auto
Hero Moto Corp
Maruti Suzuki
Tata Motors
653
507
827
1,390
2,263
2,538
2,739
516
2,420
2,616
2,692
538
7
3
(2)
4
95
70
14
555
723
114
538
776
121
556
130
188
80
1,428
106
30
66
227
202
679
238
1,541
890
90
200
36
723
581
119
392
1,555
2,783
83
202
24
321
58
Auto Ancilary
Amara Raja Batteries
Balkrishna Industries
Suprajit Industries
Capital Goods
BHEL
Crompton - Cons
Cummins
Engineers India
Larsen & Toubro - Cons
Thermax
Triveni Turbine
Voltas
Cement
JKLC
UTCEM
45
Consumer
Asian Paints
Berger Paints
Dabur
HUL
ITC
Page Ind
Pidilite Ind
Relaxo Footwear
Titan Ind
Whirlpool India
` mn)
Net Sales (`
FY15E
` mn)
EBIDTA (`
FY15E
FY16E
FY14
` mn)
PAT (`
FY15E
FY16E
4,716
3,674
1,881
1,440
2,312
1,768
2,966
2,139
FY16E
FY14
19,094
20,373
23,404
23,797
2,890
2,534
3,728
3,118
201,583
252,755
444,506
2,328,337
223,967
277,621
498,282
2,590,546
259,449
308,196
566,342
2,935,577
41,552
35,401
52,035
348,378
45,249
41,589
57,801
383,401
(3)
7
6
34,367
35,767
5,452
43,058
41,336
6,552
48,635
49,728
7,938
5,564
8,938
931
7,126
10,389
1,068
8,219
12,503
1,286
3,674
4,884
499
4,384
5,389
637
5,106
6,815
774
200
240
565
300
1,694
674
98
225
(12)
19
(17)
26
10
(24)
8
13
391,088
134,806
42,475
18,844
851,284
50,999
5,057
52,660
328,933
149,618
47,982
18,992
973,733
54,008
6,794
58,984
338,233
166,404
57,135
22,535
1,151,687
60,249
8,354
65,836
45,198
6,820
7,099
3,793
107,543
4,373
1,038
2,656
32,906
9,833
8,062
3,280
105,129
4,449
1,500
3,651
34,759
13,814
10,164
5,017
134,916
5,588
1,936
5,029
34,607
2,443
6,000
4,825
45,680
2,460
684
2,454
24,132
4,691
7,034
4,418
46,547
2,628
983
2,749
25,331
7,830
7,853
5,674
64,970
3,510
1,292
3,768
305
2,651
309
2,851
1
8
20,566
200,779
25,210
233,190
31,925
271,412
3,020
36,160
4,130
46,291
6,065
58,177
1,115
21,445
1,385
26,018
213
32,888
616
344
222
708
343
7,440
386
400
363
441
590
330
225
742
345
6,745
417
450
345
483
(4)
(4)
1
5
1
(9)
8
13
(5)
10
127,148
38,417
70,804
280,191
332,386
11,732
42,832
12,120
109,274
28,331
146,280
44,146
82,502
320,241
383,415
14,658
50,344
14,664
125,358
33,173
170,581
50,753
95,680
366,515
443,424
18,488
59,250
17,652
146,437
39,508
19,979
4,236
11,416
44,753
124,549
2,366
6,770
1,465
10,443
2,100
23,624
5,053
13,936
53,525
144,249
3,014
8,053
1,798
12,597
3,288
27,741
6,017
16,517
62,793
168,823
3,878
9,689
2,203
15,296
4,179
12,288
2,432
9,139
35,527
87,852
1,537
4,619
656
7,348
1,229
15,349
3,079
10,889
41,615
101,564
1,952
5,731
872
8,631
2,064
18,257
3,692
13,031
47,958
119,977
2,508
7,103
1,155
10,969
2,788
54,086
33,803
49,221
21,091
66,828
28,525
443,272 139,911
37,216
43,763
24,486
29,028
33,955
40,651
163,481 192,546
DOLAT CAPITAL
Mcap
(`
` bn)
India Research
August 25, 2014
Valuation Matrix
Agrochemicals
PI Industries
Rallis
60
46
439
238
479
231
9
(3)
13.8
7.4
Auto
Bajaj Auto
Hero Moto Corp
Maruti Suzuki
Tata Motors
653
507
827
1,390
2,263
2,538
2,739
516
2,420
2,616
2,692
538
7
3
(2)
4
117.9
105.6
94.5
43.5
95
70
14
555
723
114
538
776
121
(3)
7
6
21.5
50.5
4.2
25.7
55.7
5.3
Capital Goods
BHEL
556
Crompton - Cons
130
Cummins
188
Engineers India
80
Larsen & Toubro - Cons1,428
Thermax
106
Triveni Turbine
30
Voltas
66
227
202
679
238
1,541
890
90
200
200
240
565
300
1,694
674
98
225
(12)
19
(17)
26
10
(24)
8
13
14.1
3.9
21.6
14.3
49.3
20.6
2.1
7.4
9.9
7.5
25.4
13.1
50.2
22.1
3.0
8.3
Cement
JKLC
UTCEM
36
723
305
2,651
309
2,851
1
8
581
119
392
1,555
2,783
83
202
24
321
58
616
344
222
708
343
7,440
386
400
363
441
590
330
225
742
345
6,745
417
450
345
483
(4)
(4)
1
5
1
(9)
8
13
(5)
10
Consumer
Asian Paints
Berger Paints
Dabur
HUL
ITC
Page Ind
Pidilite Ind
Relaxo Footwear
Titan Ind
Whirlpool India
FY14
17.0
9.1
P/E (x)
FY14 FY15E
FY16E
FY14
ROE (%)
FY15E
FY16E
EV/EBITDA(x)
FY14 FY15E FY16E
Mcap/Sales (x)
FY14 FY15E FY16E
21.8
11.0
31.8
32.1
25.8
26.2
20.1
21.6
30.7
21.5
29.1
22.9
28.8
23.7
20.9
18.5
16.0
15.0
12.3
12.6
3.8
2.7
3.1
2.3
2.6
2.0
128.6 151.2
122.6 145.4
112.4 134.6
50.8 59.8
19.1
24.0
29.0
11.9
17.5
20.7
24.4
10.2
14.9
17.5
20.3
8.6
38.6
39.8
14.1
27.1
35.2
40.8
15.2
22.3
34.1
41.5
16.8
21.3
15.6
14.4
16.2
6.1
13.8
12.3
14.4
5.6
11.2
10.4
12.2
4.8
3.2
2.0
1.9
0.7
2.9
1.8
1.7
0.6
2.5
1.6
1.5
0.6
29.9
70.5
6.5
25.8
14.3
27.4
21.6
13.0
21.5
18.6
10.3
17.7
30.3
29.3
26.9
28.2
24.9
27.7
26.0
24.6
27.0
16.7
10.5
16.3
13.1
9.1
14.2
11.1
7.2
11.7
2.8
2.0
2.5
2.2
1.7
2.1
1.9
1.4
1.7
10.3
12.5
28.3
16.8
70.1
29.5
3.9
11.4
16.1
51.8
31.4
16.6
31.3
43.1
43.6
27.0
23.0
27.0
26.8
18.2
30.7
40.4
30.3
24.1
21.9
16.2
24.0
14.1
22.0
30.2
23.1
17.6
10.9
6.8
24.2
20.5
12.8
12.6
42.1
13.0
7.1
12.3
22.9
17.5
11.9
12.4
45.5
14.3
7.1
18.1
25.9
21.0
15.2
15.1
43.6
17.2
9.3
21.0
26.4
14.6
20.1
25.2
28.8
22.6
11.8
15.1
23.1
19.5
21.1
23.2
19.3
16.3
10.7
10.9
18.4
12.3
17.5
18.9
14.3
11.5
1.4
1.0
4.4
4.3
1.7
2.1
5.9
1.3
1.7
0.9
3.9
4.2
1.5
2.0
4.4
1.1
1.6
0.8
3.3
3.6
1.2
1.8
3.6
1.0
9.5
75.6
11.8 18.1
94.9 119.9
32.2
30.3
25.9
24.1
16.8
16.1
9.0
12.8
10.5
14.3
14.5
15.8
15.9
16.2
12.4
12.8
8.2
10.3
1.7
0.4
1.4
0.3
1.1
0.3
12.8
7.0
5.2
16.4
10.8
137.8
9.0
11.0
8.3
9.7
16.0 19.0
8.9 10.7
6.2
7.5
18.9 21.2
12.8 15.1
175.0 224.8
11.2 13.9
14.5 19.2
9.7 12.4
16.3 22.0
48.1
49.1
42.7
43.2
31.8
54.0
42.8
36.4
43.9
45.5
38.5
38.7
35.8
37.5
26.9
42.5
34.4
27.6
37.4
27.1
32.4
32.1
29.6
33.4
22.7
33.1
27.7
20.8
29.4
20.1
33.0
23.0
38.0
111.0
36.1
61.2
24.3
24.0
32.8
16.6
34.0
25.0
37.0
94.0
37.3
58.1
25.1
24.0
30.4
21.8
34.0
25.0
37.0
81.0
38.6
56.4
25.7
25.0
30.9
22.8
23.6
21.0
29.2
26.1
20.4
36.0
27.0
17.4
31.0
25.3
19.5
17.4
23.6
22.4
17.4
28.0
23.0
14.1
25.4
15.8
16.2
14.4
20.0
19.2
14.6
22.0
19.0
11.3
20.4
11.8
3.8
2.3
4.7
4.4
8.0
7.0
4.4
1.9
2.9
2.0
3.3
2.0
4.0
3.9
7.0
5.7
3.8
1.6
2.6
1.7
2.8
1.7
3.5
3.4
6.0
4.6
3.2
1.3
2.2
1.4
DOLAT CAPITAL
CMP
`)
(`
Auto Ancilary
Amara Raja Batteries
Balkrishna Industries
Suprajit Industries
TP Upside
`)
(`
(%)
`)
EPS (`
FY15E FY16E
Mcap
(`
` bn)
India Research
August 25, 2014
Companies
46
Mcap
(`
` bn)
Upside
(%)
FY14
371
462
88
358
177
388
342
74
327
144
5
(26)
(16)
(9)
(19)
39,174
31,429
9,439
31,796
417,758
37
1,091
2,052
28
88
92
22
7
297
50
4,824
529
1,364
1,259
1,579
3,585
150
1,057
440
370
225
3,535
1,258
2,465
2,282
554
1,200
1,750
3,875
190
920
585
500
215
4,040
1,135
2,770
2,500
555
(5)
11
8
27
(13)
33
35
(4)
14
(10)
12
10
0
Midcap
Astral Poly
Supreme Ind.
46
70
823
581
888
512
Pharmaceuticals
Aurobindo
Biocon
Cadila Healthcare
Cipla
Divis Labs
Dr. Reddys Labs
Glenmark
GSK Pharma*
Ipca Labs
Lupin
Sun Pharma
236
95
251
400
207
481
195
211
94
560
1,775
811
474
1,226
498
1,556
2,826
719
2,491
743
1,251
857
845
537
1,309
535
1,648
2,968
769
2,166
648
1,455
893
47
* Dec year end.
` mn)
EBIDTA (`
FY15E
FY16E
FY14
` mn)
PAT (`
FY15E
FY16E
10,167
6,671
9,471
7,742
18,758
3,604
3,734
3,848
5,087
6,978
4,169
4,383
3,990
4,911
6,687
4,531
4,584
4,506
5,412
9,100
FY16E
FY14
43,733
35,247
9,936
33,052
425,654
50,317
38,951
10,758
34,718
445,879
7,824
5,677
8,324
6,877
14,587
8,902
6,992
8,710
7,007
16,458
8,410
329,180
501,330
26,940
30,316
25,939
23,050
3,499
37,413
16,692
818,094
188,313
434,269
9,245
368,912
537,019
29,650
35,514
62,087
24,666
3,822
43,356
18,859
950,618
213,974
468,973
10,825
426,139
615,064
33,652
41,035
70,792
29,197
4,336
49,421
22,123
1,095,963
244,728
516,217
3,206
79,350
120,410
3,669
6,100
3,893
2,896
592
13,994
4,303
238,079
36,615
89,354
3,130
85,035
136,661
4,062
7,144
9,548
3,124
662
17,571
4,600
268,278
38,206
95,435
8
(12)
10,732
39,120
13,964
45,854
17,961
49,587
1,557
5,654
2,053
6,049
2,658
7,045
772
3,037
1,215
3,250
1,664
4,158
4
13
7
7
6
5
7
(13)
(13)
16
4
80,385
28,773
70,601
101,004
25,321
133,586
60,069
25,462
32,818
112,865
160,044
113,616
33,525
83,462
117,184
30,360
157,831
70,652
26,773
36,144
135,925
183,573
127,202
43,441
96,874
136,834
36,542
181,262
82,158
30,010
43,198
158,944
212,541
21,328
6,871
12,001
21,331
10,145
33,217
13,101
5,221
8,106
30,028
71,956
22,799
8,063
15,774
23,671
12,205
38,238
15,739
5,908
8,641
38,059
81,999
28,293
10,643
19,280
28,735
14,726
42,845
18,398
7,162
10,373
46,094
94,624
13,759
4,138
8,036
13,872
7,733
21,512
7,599
5,019
5,508
18,363
57,218
13,791
4,697
10,724
15,453
9,164
25,022
9,072
5,262
5,624
22,515
58,444
17,581
5,966
13,401
19,507
10,938
28,047
10,978
6,115
6,814
27,140
66,063
3,594
2,557
98,506
63,710
157,725 106,480
4,889
2,489
8,258
4,268
12,161
3,027
4,007
2,305
803
627
19,798
13,593
5,506
2,791
308,820 191,087
47,388
30,287
105,401
77,529
2,467
2,835
70,200
81,730
120,220 138,328
2,885
3,211
5,287
5,919
7,660
9,757
2,383
3,015
660
778
15,380
16,995
2,734
3,496
217,266 246,490
30,079
36,712
81,827
90,566
DOLAT CAPITAL
Target
`)
(`
Energy
Indraprastha Gas
52
Gujarat Gas
59
GSPL
50
Castrol India
171
Petronet LNG
133
IT
Eclerx
HCL Tech
Infosys
KPIT Technologies
Mindtree
Mphasis
NIIT Tech
Nucleus
OFSS
Persistent
TCS
Tech mahindra
Wipro
` mn)
Net Sales (`
FY15E
CMP
`)
(`
India Research
August 25, 2014
Companies
Mcap
(`
` bn)
CMP Target Upside

`)
`)
(`
(`
(%)
Energy
Indraprastha Gas
52
371
Gujarat Gas
59
462
GSPL
50
88
Castrol India
171
358
Petronet LNG
133
177
IT
Eclerx
HCL Tech
Infosys
KPIT Technologies
Mindtree
Mphasis
NIIT Tech
Nucleus
OFSS
Persistent
TCS
Tech mahindra
Wipro
Midcap
Astral Poly
Supreme Ind.
`)
EPS (`
FY15E FY16E
P/E (x)
FY14 FY15E
FY16E
FY14
ROE (%)
FY15E
FY16E
EV/EBITDA(x)
Mcap/Sales (x)
388
342
74
327
144
5
(26)
(16)
(9)
(19)
25.7
29.1
6.8
10.3
9.3
29.8
31.8
7.1
9.9
8.9
32.4
34.2
8.0
10.9
12.1
14.4
15.9
13.0
34.8
19.0
12.5
14.5
12.4
36.0
19.9
11.5
13.5
11.0
32.7
14.6
22.1
34.5
19.8
72.6
15.4
21.7
32.1
17.8
73.2
15.2
20.2
31.8
17.1
86.0
17.4
7.6
11.5
6.5
24.0
7.3
6.7
9.7
6.1
23.6
6.5
5.5
9.2
5.8
21.1
6.1
1.3
1.9
5.3
5.4
0.3
1.2
1.7
5.0
5.2
0.3
1.0
1.5
4.6
4.9
0.3
37
1,091
2,052
28
88
92
22
7
297
50
4,824
529
1,364
1,259
1,579
3,585
150
1,057
440
370
225
3,535
1,258
2,465
2,282
554
1,200
1,750
3,875
190
920
585
500
215
4,040
1,135
2,770
2,500
555
(5)
11
8
27
(13)
33
35
(4)
14
(10)
12
10
0
82.8
92.2
186.2
13.4
54.0
14.4
38.5
19.4
161.5
62.3
97.6
127.5
31.7
79.9
101.6
210.2
15.6
60.8
36.5
39.8
20.4
182.8
74.7
111.0
126.3
33.4
91.9
118.3
241.8
17.3
70.8
46.4
50.4
24.0
202.0
87.4
125.9
158.9
37.0
15.2
17.1
19.3
11.2
19.6
12.7
9.6
11.6
21.9
20.2
25.2
17.9
17.5
15.8
15.5
17.1
9.6
17.4
12.1
9.3
11.0
19.3
16.9
22.2
18.1
16.6
13.7
13.4
14.8
8.7
14.9
9.5
7.3
9.4
17.5
14.4
19.6
14.4
15.0
49.6
37.4
24.4
21.4
28.3
14.5
19.9
17.3
16.8
22.8
40.7
35.2
24.9
36.4
31.0
23.5
20.5
27.1
14.6
18.0
16.6
16.1
22.7
36.3
28.9
22.3
33.5
28.4
23.3
18.9
24.1
17.3
19.8
17.2
15.2
22.1
33.1
27.7
21.1
10.1
11.5
14.2
7.3
11.9
7.3
7.3
5.9
15.0
9.6
18.4
12.2
12.9
10.3
10.7
12.5
6.6
10.1
7.1
6.8
5.3
11.9
9.0
16.3
11.7
12.1
9.0
9.3
10.8
5.5
8.8
5.6
5.3
4.4
10.6
7.5
14.2
9.4
10.9
4.3
3.3
4.1
1.0
2.9
1.5
1.0
2.1
8.0
3.0
5.9
2.8
3.1
4.0
3.0
3.8
0.9
2.5
1.5
0.9
1.9
6.9
2.7
5.1
2.5
2.9
3.4
2.6
3.3
0.8
2.2
1.3
0.8
1.7
6.0
2.3
4.4
2.2
2.6
46
70
823
581
888
512
8
(12)
13.7
23.9
21.6
25.6
29.6
32.7
59.9
24.3
38.1
22.7
27.8
17.8
27.9
31.2
32.7
30.4
32.9
31.4
27.1
12.8
19.9
10.5
14.9
9.8
4.3
1.8
3.3
1.5
2.6
1.4
236
95
251
400
207
481
195
211
94
560
1,775
811
474
1,226
498
1,556
2,826
719
2,491
743
1,251
857
845
537
1,309
535
1,648
2,968
769
2,166
648
1,455
893
4
13
7
7
6
5
7
(13)
(13)
16
4
47.2
20.7
39.2
17.3
58.3
126.5
28.0
56.2
43.6
41.0
15.5
47.4 60.4
23.5 29.8
52.4 65.5
19.2 24.3
69.0 82.4
147.1 164.9
33.5 40.5
62.1 72.2
44.6 54.0
50.3 60.6
28.2 31.9
17.2
22.9
31.2
28.8
26.7
22.3
25.7
44.3
17.0
30.5
55.4
17.1
20.2
23.4
25.9
22.5
19.2
21.5
40.1
16.7
24.9
30.4
13.4
15.9
18.7
20.5
18.9
17.1
17.8
34.5
13.8
20.6
26.9
36.0
14.5
24.3
14.6
28.0
25.8
18.0
23.6
31.4
30.9
40.9
30.2
14.7
27.1
14.4
27.4
24.1
24.8
26.5
25.6
29.1
34.2
29.1
16.8
27.7
15.9
27.0
22.0
24.0
31.1
25.0
27.4
30.8
11.1
15.1
21.6
16.2
19.6
14.5
14.0
36.6
11.7
17.8
21.9
10.4
12.9
16.2
14.5
16.3
12.2
11.3
32.7
10.7
13.8
18.7
8.1
9.7
13.0
11.6
13.6
10.4
9.4
27.0
8.8
11.1
15.7
2.6
3.6
3.3
3.7
7.9
3.6
2.7
8.4
2.9
4.8
10.1
1.8
3.1
2.8
3.2
6.6
3.1
2.3
8.0
2.6
4.0
8.8
1.7
2.4
2.4
2.7
5.5
2.7
2.0
7.1
2.2
3.4
7.6
DOLAT CAPITAL
48
Pharmaceuticals
Aurobindo
Biocon
Cadila Healthcare
Cipla
Divis Labs
Dr. Reddys Labs
Glenmark
GSK Pharma*
Ipca Labs
Lupin
Sun Pharma
* Dec year end.
FY14
India Research
August 25, 2014
Companies
Financials
CMP
`)
(`
Target
`)
(`
Upside
(%)
Axis Bank
949
Bank of Baroda
387
Bank of India
174
City Union Bank
47
HDFC Bank
2,041
ICICI Bank
1,779
ING Vysya Bank
122
Karur Vysya Bank
51
Punjab National Bank 348
State Bank of India
1,884
Union Bank
132
Yes Bank
242
402
920
292
78
847
1,538
640
482
984
2,524
221
584
455
1,070
360
85
880
1,730
720
570
1,150
2,858
250
673
13
16
23
8
4
13
13
18
17
13
13
15
Mcap
(`
` bn)
CMP
`)
(`
Target
`)
(`
Axis Bank
949
Bank of Baroda
387
Bank of India
174
City Union Bank
47
HDFC Bank
2,041
ICICI Bank
1,779
ING Vysya Bank
122
Karur Vysya Bank
51
Punjab National Bank 348
State Bank of India
1,884
Union Bank
132
Yes Bank
242
402
920
292
78
847
1,538
640
482
984
2,524
221
584
455
1,070
360
85
880
1,730
720
570
1,150
2,858
250
673
Financials
Operating Income
FY15E
FY16E
` mn)
PAT (`
FY15E
FY14
NII
FY15E
FY16E
FY14
119,516
119,653
108,304
7,594
184,826
164,756
17,532
12,837
161,460
492,822
78,793
27,163
138,279
144,667
136,046
8,676
216,444
182,723
19,770
15,507
178,476
591,734
87,816
33,725
164,765
177,301
161,765
10,581
265,554
219,215
23,577
19,589
211,299
713,607
102,996
41,080
114,561
92,910
84,228
5,810
143,601
165,947
11,275
8,378
113,847
321,092
52,181
26,880
128,771
112,216
105,597
6,470
174,282
180,594
13,635
10,840
124,026
385,760
56,480
34,501
153,280
136,262
124,491
8,150
215,219
213,551
16,702
13,728
146,988
457,188
64,850
42,635
62,177
45,411
27,292
3,471
84,784
98,106
6,579
4,296
33,426
108,912
16,962
16,178
Upside
(%)
FY14
ROE (%)
FY15E
FY16E
FY14
ROA (%)
FY15E
FY16E
FY14
P/E (x)
FY15E
FY16E
13
16
23
8
4
13
13
18
17
13
13
15
17.4
13.8
11.2
18.3
21.3
17.0
10.3
13.4
10.2
10.0
10.4
25.0
17.1
15.0
12.8
16.9
21.0
16.4
10.8
16.1
12.6
11.9
11.0
21.7
18.2
16.3
15.9
17.3
22.1
17.5
12.5
17.6
15.2
14.8
12.8
20.0
1.7
0.8
0.5
1.4
1.9
1.7
1.1
0.9
0.7
0.6
0.5
1.6
1.7
0.8
0.6
1.5
1.9
1.7
1.2
1.1
0.8
0.8
0.5
1.7
1.8
0.8
0.7
1.6
2.0
1.8
1.4
1.2
0.9
0.9
0.6
1.8
15.2
8.6
6.9
12.2
24.0
14.4
18.4
12.0
10.7
12.5
8.2
13.0
13.5
7.1
5.3
11.6
20.4
13.2
15.4
9.4
7.8
9.6
7.2
11.8
11.0
5.7
3.8
9.2
16.3
11.0
12.0
7.2
5.8
6.9
5.7
9.4
FY14
FY16E
FY14
70,213 85,853
55,732 69,252
35,220 49,254
3,981
5,012
99,472 124,440
106,652 127,996
7,857 10,068
6,163
8,123
45,913 61,784
148,112 205,355
19,191 24,304
20,473 25,670
26
106
42
6.4
35
85
35
40
92
152
27
45
`)
EPS (`)
FY15E FY16E
30
129
55
6.8
41
92
42
51
127
198
30
49
37
161
77
8.5
52
111
53
67
171
275
39
62
P/ABV(x)
FY14 FY15E FY16E
2.54
1.37
1.00
2.33
4.77
2.44
1.76
1.62
1.45
1.80
1.20
2.97
2.22
1.23
0.89
1.88
4.03
2.16
1.63
1.41
1.29
1.79
1.08
2.07
1.92
1.05
0.76
1.61
3.38
1.91
1.45
1.26
1.09
1.52
0.94
1.75
DOLAT CAPITAL
Mcap
(`
` bn)
India Research
August 25, 2014
Valuation Matrix
49
DOLAT CAPITAL
BUY
Upside above 20%
ACCUMULATE
Upside above 5% and up to 20%
REDUCE
Upside of upto 5% or downside of upto 15%
SELL
Downside of more than 15%
Analyst
Sector/Industry/Coverage
E-mail
Tel.+91-22-4096 9700
Amit Khurana, CFA

Amit Purohit
Kunal Dalal
Milind Bhangale
Pawan Parakh
Priyank Chandra
Rahul Jain
Rajiv Pathak
Prachi Save
Co-Head Equities and Head of Research

Consumer
Auto & Auto Ancillaries
Pharma
Capital Good
Oil & Gas
IT Services
Financials
Derivatives
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
Associates
Sector/Industry/Coverage
E-mail
Afshan Sayyad
Abhishek Lodhiya
Avinash Kumar
Devanshi Dhruva
Manish Raj
Pranav Joshi
Agrochemicals
Real Estate
Capital Goods
Economy
Cement
Financials
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
Equity Sales/Trading
Designation
E-mail
Purvag Shah
Vikram Babulkar
Kapil Yadav
Parthiv Dalal
P. Sridhar
Chandrakant Ware
Jatin Padharia
Shirish Thakkar
Principal
Co-Head Equities and Head of Sales
AVP - Institutional Sales
AVP - Institutional Sales
Head Sales Trading
Senior Sales Trader
Head of Sales Trading - Derivatives
Sales Trader - Derivatives
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
+91-22-40969745
+91-22-40969724
+91-22-40969749
+91-22-40969731
+91-22-40969712
+91-22-40969737
+91-22-40969754
+91-22-40969750
+91-22-40969733
Tel.+91-22-4096 9700
+91-22-40969726
+91-22-40969753
+91-22-40969764
+91-22-40969756
+91-22-40969725
+91-22-40969706
Tel.+91-22-4096 9797
+91-22-40969747
+91-22-40969746
+91-22-40969735
+91-22-40969705
+91-22-40969728
+91-22-40969707
+91-22-40969703
+91-22-40969702
Dolat Capital Market Pvt. Ltd.

20, Rajabahadur Mansion, 1st Floor, Ambalal Doshi Marg, Fort, Mumbai - 400 001
This report contains a compilation of publicly available information, internally developed data and other sources believed to be reliable. While
all reasonable care has been taken to ensure that the facts stated are accurate and the opinion given are fair and reasonable, we do not take
any responsibility for inaccuracy or omission of any information and will not be liable for any loss or damage of any kind suffered by use of
or reliance placed upon this information. For Pvt. Circulation & Research Purpose only.
Our Research reports are also available on Reuters, Thomson Publishers, DowJones and Bloomberg (DCML <GO>)

Dolat Preferred

Uploaded by

Document Informationclick to expand document information

Copyright:

Available Formats

Dolat Preferred

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Dolat Preferred

Uploaded by

Copyright:

Available Formats

DOLAT CAPITAL

Key issues pending /

Oil & Gas

Gas price hike

Significant, as it impacts ONGC and RIL

If Vodafone is made to finally pay up, it

States share for higher

Significant progress made by offering

LPG subsidies being brought down on

Amit Khurana - Head of Research

Recent correction provides attractive opportunity to enter the stock with

Expect recovery in earnings from H2FY15 onwards led by improved

Larsen & Toubro

Proxy play on recovery in infrastructure spend in India. Recent correction

PTC India Financial (PFS)

Out of Preferred Buy

We believe the inspection observation (Form 483) will be an overhang

Karur Vysya Bank

An improvement in overall asset quality is likely to be back-ended in

State Bank of India

Fundamentals stand intact, however valuations look expensive at

Potential upside remains capped post the recent run-up. Delayed

* With reference to our note dated 9th June 2014

Nifty EPS & P/E Estimates

Amit Khurana - Head of Research

Amit Khurana - Head of Research

Earnings Growth Aggregates - Unbundled

Amit Khurana - Head of Research

Auto and Ancillary

Net Sales (%)

Karur Vysya Bank

Net Sales (%)

Amit Khurana - Head of Research

FY15E (Top Ten Upgrades)

ING Vysya Bank

FY15E (Top Ten Downgrades)

Amit Khurana - Head of Research

Our Preferred Picks* v/s Benchmark Indices (QTD)

Domestic demand expected to pickup in H2FY15,

Expect recovery in orderbook from H2FY15.

Demand recovery post H2FY15 onwards.

Raising weightage on discretionary and organised

Prefer stock specific approach.

Private banks are likely to outperform in the medium

Cutting back on IT as INR remains elevated, and

Still retain our weightage on sustenance of earnings

Amit Khurana - Head of Research

DOLAT PREFERRED BUY PICKS

Capital Goods Crompton Greaves

FY14 FY15E FY16E

FY14 FY15E FY16E

FY14 FY15E FY16E

FY14 FY15E FY16E

FY14 FY15E FY16E

FY14 FY15E FY16E

FY14 FY15E FY16E

City Union Bank

FY14 FY15E FY16E